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THE IMPORTANCE OF NONCAPPED VIRAL GENOMIC RNA TO ALPHAVIRAL 
INFECTION AND PATHOGENESIS 
Autumn LaPointe 
March 25, 2021 
Alphaviruses are mosquito-borne arboviruses that have a positive sense, 
single-stranded RNA genome, which are capable of causing severe disease and 
thus pose a significant burden to public health. During alphaviral replication, 
significant quantities of viral genomic RNAs that lack the canonical alphaviral 5’ 
cap structure are produced and packaged into viral particles, despite the fact that 
these noncapped genomes cannot be translated and are essentially 
noninfectious. The production and packaging of the noncapped genomes has 
been found to be true for infections across multiple vertebrate and invertebrate 
cell lines and alphavirus species, although the proportion of ncgRNA produced 
differs. Despite knowing this, the importance of the noncapped genomic vRNA 
(ncgRNA) to alphaviral infection has yet to be fully characterized. In this 
dissertation, the importance of the ncgRNAs to alphaviral infection was assessed 
by using mutations of the nsP1 protein of Sindbis virus (SINV), which altered the 
synthesis of the ncgRNAs during infection by modulating the protein’s capping 
efficiency. It was found that decreasing ncgRNA production lead to decreased 
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viral growth kinetics via decreased particle production; whereas increasing 
ncgRNA production led to wild type growth kinetics and particle production.  
In addition to being necessary for efficient viral replication in vitro, we also 
found that the noncapped genomic RNA was critical for alphaviral pathogenesis. 
Mice infected with the increased ncgRNA mutant exhibited wild type rates weight 
loss, and neurological symptoms, but exhibited a slight decrease in mortality. 
Conversely, the mice infected with the decreased ncgRNA mutant showed 
significantly reduced mortality and morbidity compared to mice infected with wild 
type virus. Interestingly, both mutants had modestly reduced viral titer in the brain 
compared to wild type virus. Importantly, examination of the brain tissue revealed 
that mice infected with the decreased ncgRNA mutant had significantly reduced 
cell death, immune cell infiltration, and expression of proinflammatory cytokines 
compared to the increased ncgRNA mutant and wild type virus.  
Collectively, these data indicate that the ncgRNA play an important role 
during alphaviral replication and pathogenesis by increasing the efficiency of 
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Alphaviruses as Pathogens 
Alphaviruses are mosquito-borne, single-stranded RNA viruses that have 
been the cause of both localized outbreaks and large epidemics of severe 
disease. Transmission of these viruses largely occurs between a mosquito 
vector, primarily Aedes, Anopheles, and Culex genera, and a vertebrate host, 
typically rodents and birds, in an enzootic cycle (Fig. 1.1) [1]. However, epizootic 
spillover events do occur that lead to infection of humans and horses. Although 
these tend to be dead-end hosts, recent alphavirus epidemics have shown the 
ability of these viruses to adapt for more efficient interhuman transmission [2]. 
Due to the expansion of the geographic area in which the mosquito vectors can 
be found, alphaviruses have an increased capacity to emerge into naïve 
populations, making them a significant threat to public health. 
Alphaviruses are largely classified as either arthritogenic or encephalitic 
based on the symptoms of infection. Arthritogenic alphaviral infection causes 
disease that can vary from mild to severe and can persist for several months to 
years past the acute phase of infection [3]. This includes Chikungunya (CHIKV) 
and Ross River Virus (RRV) which are capable of causing debilitating 
polyarthritis as well as the model alphavirus Sindbis virus (SINV), which is the 
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causative agent of rash-arthritic diseases like Pogosta disease, Ockelbo disease, 
and Karelian fever [4-8].  While not associated with high rates of mortality, the 
high morbidity of arthritogenic alphaviral disease results in a high economic 
burden that is particularly damaging in regions where labor-intensive work is 
prevalent [9, 10].  The encephalitic alphaviruses include Venezuelan, Eastern, 
and Western Equine Encephalitis viruses (VEEV, EEEV, and WEEV) and are 
capable of causing severe meningitis and encephalitis, as well as long lasting 
sequelae such as seizures, paralysis, and cognitive deficits in survivors [11-14]. 
These viruses, while comparatively rare in regards to their incidence, typically 
have high mortality rates, especially in comparison to the arthritogenic 
alphaviruses, with viruses like EEEV having mortality rates as high as 70% in 
symptomatic individuals [15].  
As part of their transmission cycles, alphaviruses infect both mosquitos as 
well as vertebrates. Infection of the mosquito vector begins with the ingestion of a 
bloodmeal from an infected vertebrate host. Viral infection is initiated in the 
midgut, where the virus infects and replicates within epithelial cells lining the gut 
[16, 17]. Once the virus has escaped from the midgut, it then spreads to the 
hemocoel, an open body cavity where hemolymph is circulated. Once in the 
hemolymph, the virus is spread to secondary tissues, including the salivary 
glands, which is the main site of viral transmission [16].  Once the salivary glands 
have been infected, the virus can be released into the salivary ducts and 
transmitted orally to a vertebrate host during the mosquito’s next blood meal. The 
extrinsic incubation period, which is the time from ingestion of the infected 
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bloodmeal to when the mosquito is able to transmit the virus, is ~2-7 days for 
alphaviruses [1]. While the mosquito immune system is able to limit viral 
replication, it is unable to completely clear the virus, thus allowing the virus to be 
continuously transmitted to new vertebrate hosts for the life of the mosquito [18]. 
After being transmitted to a vertebrate host, the virus replicates locally at the site 
of inoculation in the skin, specifically dermal fibroblasts, enterocytes, and 
keratinocytes [19]. Infection of Langerhan’s cells and dendritic cells in the skin 
leads to infection of the lymph nodes draining the site of inoculation. Once 
viremia occurs, the virus is then able to disseminate to other tissues, including 
lymphoid tissues, joints, and the central nervous system including the brain [1].  
Which secondary organs the virus disseminates to is largely dependent on 
the particular alphavirus species, as tissue tropism differs greatly among the 
alphaviruses. The arthritogenic alphaviruses primarily target the cells of the skin, 
joints, and muscle, while the encephalitic alphaviruses target those of the 
nervous system [1]. Inflammation in these target regions in response to viral 
infection then ultimately leads to the development of alphaviral disease. The time 
from infection to onset of symptoms, termed the intrinsic incubation period, 
ranges from 2-10 days in people for both the arthritic and encephalitic 
alphaviruses [20, 21]. 
Despite the threat that alphaviruses pose to public health, there are no 
antiviral strategies or vaccines which are either safe or effective for preventing 
alphaviral infection or treating alphaviral disease. This deficit of viable 
therapeutics highlights the need to better understand the mechanisms behind 
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alphaviral infection in order to develop novel antiviral strategies for the mitigation 
of alphaviral disease. 
 
A Brief Overview of the Alphaviral Life Cycle 
 Infection begins with the E2 glycoproteins in the viral envelope binding to 
receptors on the surface of the host cell (Fig. 1.2). After binding, the virus rapidly 
enters the host cell via receptor mediated endocytosis, which forms an 
endosome containing the viral particle [22, 23]. As the endosome transitions from 
early to late, the low pH of the maturing endosome causes conformational 
changes in the glycoproteins which allows the envelope to fuse with the 
endosomal membrane, releasing the viral nucleocapsid into the cell cytoplasm 
[24]. Membrane fusion is mediated by the viral E1 glycoprotein after the exposure 
of the fusion loop during the conformational change in response to pH [25]. 
Following the release of the nucleocapsid core, the host 60S ribosomal RNA 
interacts with the capsid protein and facilitates the disassembly of the 
nucleocapsid, resulting in the viral genome being released into the cytoplasm 
[26]. The genome then interacts with host factors and is immediately translated 
by host cell machinery, producing the nonstructural polyprotein P1234, which is 
then proteolytically cleaved via the proteolytic activities of nonstructural protein 2 
(nsP2) to form the initial viral replicase complex, P123 and nsP4. This initial 
complex uses the viral genome to synthesize the minus strand RNA that serves 
as the template for viral replication and transcription [27]. The nonstructural 
polyprotein is then further processed by nsP2 to produce the individualized 
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nonstructural proteins of the fully processed viral replicase complex (consisting of 
nsP1, nsP2, nsP3, and nsP4) [28]. The replicase complex produces the genomic 
RNA and subgenomic RNA through viral replication and transcription, 
respectively. The subgenomic RNA is translated to produce the structural 
polyprotein, consisting of the capsid protein, the glycoproteins E3; E2; and E1, 
and the 6K/transframe (TF) proteins. The capsid protein cleaves itself off of the 
structural polyprotein and associates with the newly synthesized viral genomes to 
form nucleocapsid cores [29]. The remaining structural polyprotein is targeted to 
the endoplasmic reticulum via signal sequences present in the E3 protein, and 
subsequently processed into the individual glycoproteins in the ER via the 
activities of host proteases, where they undergo post-translational modifications 
including disulfide bond rearrangement, palmitoylation, and glycosylation prior to 
being trafficked to the cell surface [30]. Newly formed mature virions are then 
released from the cell via budding, creating the envelope that contains the viral 
glycoproteins as the nucleocapsid core pushes through the host plasma 
membrane [30]. 
 
Alphavirus Genetic Organization 
The alphaviral genome is a single-strand of positive sense RNA that is 
~11.5kb in length and contains two coding regions. The first open reading frame 
is the only one expressed from the genome and codes for the nonstructural 
proteins nsP1-4, which are responsible for RNA replication (Fig. 1.3). The 
nonstructural proteins are expressed as a polyprotein, P1234, that undergoes 
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several iterations of proteolytic cleavage to form the various replication 
complexes needed to produce the minus strand template and subgenome in 
addition to more genomic RNA. The minus strand RNA, which serves as the 
template from which the genome and subgenome, is the predominant vRNA 
synthesized by a complex consisting of P123 and nsP4. Once the viral 
polyprotein has been fully cleaved into nsP1,2,3, and 4, they form the replication 
complex that synthesizes the genome and subgenome. The subgenome contains 
only the second open reading frame and is responsible for the production of the 
structural proteins. The structural proteins include the capsid protein, 
glycoproteins, and the 6k/TF protein, which are all required to form the viral 
particle. 
 
The Alphaviral Nonstructural Proteins 
As stated earlier, there are four nonstructural proteins (nsPs) encoded as 
a single polyprotein during the translation of the viral genomic RNA. These are 
named numerically in the order of their relative position to the N-terminus of the 
polyprotein. Each of the individual nsPs are necessary for viral replication with 
their primary functions in viral replication being modular in nature; and in addition 
to their viral RNA synthesis roles, several of the nsPs have critical functions 
outside of viral replication complex.  
 
The Alphaviral nsP1 Protein 
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 The ~60kDa nsP1 protein serves three primary functions during alphaviral 
infection: anchoring the replication complex, forming the pore to the replication 
spherules, and vRNA capping via methyltransferase and guanylyltransferase 
enzymatic reactions [28]. The presence of an amphipathic helix, and the 
palmitoylation of conserved cysteine residues in nsP1, allows the protein to 
anchor the replication complexes to host membranes, which is a consistent 
feature of the replication machinery of all ssRNA viruses. Binding of nsP1 to the 
host membrane starts with weak binding of the amphipathic helix to plasma 
membrane. This is followed by palmitoylation of cysteine residues within the 
amphipathic helix, which changes the properties of nsP1 to appear similar to 
those of the integral membrane proteins [31]. The interaction of the nsP1 protein 
with host membranes is associated with the formation of subcellular structures 
important to alphaviral biology, including the formation of membranous 
spherules, and the formation of filopodia at the cell surface which aid in cell-to-
cell transmission [31, 32]. The spherules are formed from host membranes, with 
the specific host membrane varying across the members of the genus, and serve 
as the site of RNA replication. In addition to anchoring the replication complex 
and lining the spherule compartment, the nsP1 protein has also been shown to 
form the pore structures that are in part responsible for controlling access to the 
replication spherules [33]. In a recent publication from Jones et al that 
determined the structure of nsP1, they demonstrated that the nsP1 proteins 
assemble into a dodecameric ring structure that would allow the protein to restrict 
access to the replication spherule. Whether the guanylytransferase or 
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methyltransferase activities of nsP1 are active while in this pore-like structure is 
unknown, but the constriction of the pore is important for keeping the dsRNA 
intermediates that form during RNA replication from being sensed by host 
proteins like MDA5, LGP2, and Dicer [34]. While the membrane binding 
properties of the nsP1 protein are dispensable to viral replication, the efficiency 
of RNA synthesis in mutants lacking membrane association is greatly impaired. 
Nonetheless, nsP1’s role as a membrane binding protein is separate from its 
function as the capping enzyme, as binding to the host membrane does not 
impact the enzymatic activity of nsP1 [35-37]. 
 The nsP1 protein’s role as the alphaviral capping enzyme has been fairly 
well characterized. Both the genome and subgenome have a Type-0 cap 
structure co-transcriptionally added to the 5’ end during RNA synthesis. The 
Type-0 cap used by alphaviruses is similar to the Type-1 cap added to eukaryotic 
mRNAs, with the major difference being that the Type-1 cap is 2’O methylated 
whereas the Type-0 cap is not [38]. The addition of the cap to the 5’ end of the 
viral RNA serves multiple critical functions in virus replication as well as how the 
vRNA interacts with the host cell. The presence of the 5’ cap structure allows the 
genome and subgenome to be readily translated using the host translation 
machinery. In addition, the 5’ cap also protects the RNA from being degraded by 
host exonucleases and prevents immune sensing of the viral RNA by host 
proteins such as RIG-I. 
The addition of the cap to the 5’ end of the vRNA is carried out in a 
stepwise fashion by nsP1 and nsP2. The methyltransferase domain of nsP1 
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transfers a methyl group from S-adenosylmethionine (SAM) to the N7 position of 
a GTP molecule. The guanylyltransferase region of nsP1 then binds the m7Gppp 
nucleotide forming a covalent link with the catalytic histidine residue (specifically 
H39 in SINV), releasing a molecule of inorganic pyrophosphate (PPi) and 
resulting in the formation of an m7GMP-nsP1 intermediate [35, 39]. By this time 
the nsP2 protein has removed the 5’ γ-phosphate from the nascent vRNA, and 
nsP1 transfers the m7GMP moiety to the vRNA molecule, resulting in the 
formation of the Type-0 7meGppA cap structure [40]. The alphaviral RNA 
capping mechanism is considered to be unconventional, as the methylation of 
the GTP and the guanylyltransferase activities are in the reverse order compared 
to how RNA capping occurs in eukaryotic cells, where the guanine moiety is 
added to the RNA first and then methylated [38].  Importantly, and as described 
in greater depth below, the capping activities of the nsP1 protein can be 
modulated via the incorporation of point mutations. 
 
The Alphaviral nsP2 Protein 
The ~90kDa nsP2 protein has several distinct domains and has a diverse 
range of functions during the viral lifecycle [28]. The protease domain of nsP2 is 
responsible for cleaving the nonstructural polyprotein in cis- and in trans- during 
viral RNA synthesis, specifically through the processing of P1234 into 
P123+nsP4 via cis-cleavage, and then further cleaving P123 into nsP1+P23, and 
later P23 into nsP2 and nsP3 via trans-cleavage events [41]. Viruses lacking this 
proteolytic activity have been shown to be unable to complete the viral lifecycle 
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as the maturation of the RNA synthetic complex is essential to viral RNA 
synthesis [42]. Additionally, in regards to viral replication and transcription the 
nsP2 protein functions as an RNA helicase and an RNA triphosphatase. The 
helicase activity of nsP2 allows it to unwind RNA secondary structures during 
viral replication [43]. As mentioned above, the RNA triphosphatase motif in nsP2 
allows it to remove a phosphate from the 5’ nucleotide, which prepares the vRNA 
for subsequent capping.  In addition to the helicase and triphosphatase domains 
the nsP2 protein has a methyltransferase domain that is presumed to be 
enzymatically inactive as it lacks the catalytic residues of known 
methyltransferase enzymes [44]. The precise function / importance of this 
domain is unknown at this time.  
In addition to the roles described above, the nsP2 protein of Old World 
alphaviruses (including SINV) is intimately involved in the shutoff of host 
transcription during viral infection [45]. The shutoff of host transcription, and its 
importance to the evasion of the host antiviral defenses are described in greater 
detail below.  
 
The Alphaviral nsP3 Protein 
Compared to the other alphaviral nonstructural proteins the alphaviral 
nsP3 protein has been enigmatic, while necessary for RNA replication, the exact 
roles that nsP3 plays in this process are poorly defined. Structurally the ~60kDa 
nsP3 protein consists of three distinct regions- an N-terminal Macrodomain, an 
Alphavirus Unique Domain (AUD), and a C-terminal hypervariable region that is 
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multiply phosphorylated during infection [28]. The N-terminal Macrodomain 
exhibits the highest level of sequence conservation across the members of the 
genus, and is known to have ADP-ribosylase activity, which has been correlated 
with its ability to disassemble and prevent stress granule formation during viral 
replication [46, 47]. The importance of ADP-ribosylation is an area of current 
study. Similarly, the AUD is not well understood, but mutational analyses of the 
domain have indicated important roles in viral RNA synthesis, particularly in 
regards to the synthesis of the subgenomic vRNAs [48]. The C-terminal 
hypervariable region includes binding motifs for many host proteins and is 
thought to act as a scaffold which may be important for the assembly of the 
replication complex [49]. Interestingly, the hypervariable region exhibits 
remarkable diversity both at the amino acid level and the identities of the specific 
interacting host factors.  
 
The Alphaviral nsP4 Protein 
The ~70kDa alphaviral nsP4 protein is the viral RNA dependent RNA 
polymerase (RdRp) [28]. Many alphaviruses produce less nsP4 than the other 
nonstructural proteins, primarily due to the presence of a leaky Opal stop codon 
at the end of nsP3 which will occasionally terminate translation before nsP4 has 
been synthesized [50]. The nsP4 protein is solely responsible for carrying out 
RNA synthesis; however, nsP4 cannot act on its own, and can only function 
properly in association with the other nonstructural proteins as the replicase 
complex [51]. Structurally the nsP4 protein is largely unremarkable when 
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compared to the RdRps of other positive-sense RNA viruses. Regardless, there 
are nuances specific to the alphaviral RdRp, including the absolute requirement 
of an N-terminal tyrosine residue for activity, the function of which is unclear at 
this time. Additionally, the alphaviral nsP4 protein is responsible for the synthesis 
of the poly(A) tail found on the positives-sense vRNAs [28]. It should be noted 
that the nsP4 protein lacks any discernable proof-reading capacity, resulting in a 
relatively high rate of mutation and the formation of a diverse quasispecies [52].  
 
The Alphaviral Structural Proteins 
 As with the nonstructural proteins, the synthesis of the structural proteins 
begins with the synthesis of a polyprotein from the subgenomic vRNA from which 
the individual proteins are generated via proteolytic processing events. While the 
subgenomic RNA is known to be capped it is believed to utilize a noncanonical 
cap-independent translation initiation mechanism [53]. This is due to the 
cessation of cap-dependent translation during alphaviral infection following the 
activation of the host PKR response leading to phosphorylation of eIF2α in 
response to the synthesis of viral dsRNA. Regardless, the translation of the 
subgenomic vRNA leads to the production of 6 structural proteins- capsid, the 
E3; E2; and E1 glycoproteins, the 6k, and transframe (TF) proteins.  
 
The Alphaviral Capsid Protein 
 The ~30kDa alphaviral capsid protein lacks a discernable beta-sheet jelly 
roll conformation, and thus, is structurally unique compared to capsids of other 
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positive-sense RNA viruses [54, 55]. Architecturally the alphaviral capsid protein 
may be broadly divided into two domains- an N-terminal polybasic region with 
little structure, and a well conserved C-terminal protease domain. The N-terminal 
region lacks mentionable sequence conservation outside of being generally 
positively charged and being relatively proline rich. Subdomains exist within the 
N-terminal domain, with specific regions having known functional roles during the 
alphaviral lifecycle. The N-terminal subdomain is believed to mitigate the 
negative charge of the vRNA in the context of the nucleocapsid [56]. Immediately 
adjacent to the RNA-binding domain is an alpha helix known to be involved in the 
formation of capsid dimers during the viral assembly process. Finally, the third 
subdomain exhibits a moderate degree of sequence conservation and is involved 
in the selection of the viral genomic RNA during packaging as well as the release 
of the genomic RNA from the nucleocapsid upon the binding of the 60S rRNA 
[56, 57]. 
 In contrast to the N-terminal domain, the C-terminal Protease domain is 
rather well conserved amongst the members of the genus. The proteolytic activity 
of the protease domain is responsible for the initial cleavage of the capsid protein 
from the structural polyprotein, after which the C-terminal tail of the capsid 
protein inactivates the protease active site via steric hindrance [58, 59].  
 In addition to the structural roles of the alphaviral capsid protein, the 
capsid protein of New World alphaviruses are responsible for the shutoff of host 




The Alphaviral Glycoproteins 
 After the cleavage of the capsid protein from the structural polyprotein 
encoded by the subgenomic RNA the signal sequence present in the E3 protein 
guides the synthesis of the remaining proteins into the host ER [60]. As with the 
nonstructural polyprotein a series of proteolytic cleavage events lead to the 
production of the individual viral glycoproteins; however, unlike the previous 
polyprotein processing events, these cleavages utilize host proteases [61, 62]. 
Initially, the 6K and E1 proteins are liberated from the polyprotein via the activity 
of signal peptidases, leaving the remaining polyprotein consisting of the 
uncleaved E3 and E2 proteins. This sub-polyprotein, termed PE2 (or P62), is 
then processed by host furin protease to form the final glycoproteins [62]. During 
this time the viral E2 and E1 glycoproteins are engaged with one another as a 
heterodimer, and the cleavage of E3 from E2 serves to prime the receptor 
complex for future entry events [63]. Also during this time, the viral glycoproteins 
are post-translationally modified as they traffic from the ER to the Golgi Complex, 
and ultimately, to the cell surface where they will interact with newly formed 
nucleocapsid cores leading to the release of mature viral particles.  
 The ~49kDa alphaviral E2 protein has three ectodomains, termed A, B, C 
relative to their position towards the N-terminus, and one subdomain D in close 
proximity to domain C [55, 64]. The functions of these domains have been 
characterized largely through the use of deletion mutants, or point mutants at the 
E1/E2 interface. Domain B is the receptor binding domain, and in the context of 
the glycoprotein heterodimer, domains A and B cover the fusion loop of the E1 
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protein. The D subdomain interacts extensively with the E3 protein during the 
maturation process. In addition, the C-terminal tail of the E2 protein interacts with 
a hydrophobic pocket on the capsid protein leading to agreement between the 
symmetries of the glycoprotein spikes and the nucleocapsid cores.  
 The ~52kDa alphaviral E1 protein has three domains, termed I, II, and III 
on the basis of their position relative to the N-terminus [55, 65]. The central 
domain of E1, domain I, connects to the flanking domains of II and III. Domain II 
contains the viral fusion loop peptide, which as described above, is obscured by 
the E2 protein until a conformational trigger in response to low pH [66]. Domain 
III is largely involved in the structural rearrangements that lead to the fusion of 
the virus and host membranes during entry.  
In addition to the major glycoproteins described above, the ~6kDa 6K and 
~8kDa TF proteins are alternatively produced during translation [67]. The 6k and 
TF proteins are encoded by the same gene, but which protein is produced is 
determined by a frameshift event at a slip site upstream of the gene [67]. The 
roles of these proteins in viral infection have not been well characterized, but 
they are known to be important for particle assembly and budding [68]. 
 
Alphaviral Arthritis in Mouse Models of Infection 
 The arthritogenic alphaviruses include Chikungunya, Ross River, Semliki 
Forest, Burmah Forest, Mayaro, and Sindbis virus. Each of these viruses have 
been demonstrated to be capable of infecting mice and causing pathogenesis, 
however the ultimate disease manifestations are dependent on the route of 
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inoculation. In order to model arthritic disease in mice, the virus is inoculated 
subcutaneously in the rear footpad, where it replicates in skin fibroblasts and 
produces high titer viremia. The virus then spreads to the muscle, skeletal 
muscle, and joints, resulting in immune infiltration and inflammation in and 
around the synovial membranes and connective tissue. This leads to the 
development of acute disease which involves biphasic swelling of the inoculated 
foot, which peaks around days 3 and 7 post inoculation in adult 
immunocompetent mice [69, 70]. While infectious virus is cleared and swelling 
goes down approximately 2 weeks post inoculation, viral RNA remains present in 
the joint for at least 16 weeks following infection. Severity and presentation of 
disease varies with age, as infection in neonatal mice results in lethal 
encephalitis (Ross, 1956; Couderc, 2009). The change in lethality and disease 
symptoms between young and adult mice is thought to largely be due to the 
maturation of the immune system, as the immune system of neonatal mice is not 
yet matured [71].  
 Severity of arthritic disease is thought to be largely mediated by the host 
immune response. This is largely supported by studies with CHIKV and RRV 
using Rag -/- mice, which are deficient in B-cells and T-cells. In RRV infection, 
viral replication and progression of disease mirrored what is seen in WT mice, 
leading to the conclusion that innate immune infiltration and cytokine production 
are what lead to inflammation in the joint [72]. However, Rag -/- mice infected 
with CHIKV show little swelling of the foot during infection, suggesting that the 
adaptive immune response plays a much larger role in induction of inflammation 
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in CHIKV compared to RRV [73]. In particular, CD4+ T-cells have been shown to 
be essential for the development of joint swelling [74]. In addition to T-cells, 
macrophages in particular have been linked to progression of disease, as mice 
treated with a drug which inhibits production of MCP-1, a major monocyte 
chemoattractant, prior to CHIKV infection developed significantly milder disease 
and exhibited reduced immune infiltration in the muscle and joint [75]. The 
adaptive immune response is known to play a much larger role in viral clearance. 
This is supported by a study which showed that Rag -/- mice infected with CHIKV 
exhibit persistent viremia and elevated viral burdens compared to wild type 
C57BL/6 mice [73]. B-cells are thought to be especially important for clearance of 
CHIKV as B-cell deficient mice are unable to clear infection and pre-treatment of 
IFNAR -/- mice with anti-CHIK antibodies was found to be sufficient to protect 
against lethality [76, 77].  
 
Alphaviral Encephalitis in Mouse Models of SINV Infection 
 The encephalitic alphaviruses include Venezuelan, Eastern, and Western 
Equine Encephalitis Virus. Even though SINV causes arthritis in humans, specific 
strains such as AR86 cause lethal encephalitis in mice and thus, SINV serves as 
a model for alphaviral neuropathogenesis in mice. Depending on the aim of the 
study, the virus is typically inoculated either directly into the brain through 
intracranial injection or subcutaneously in the rear footpad. During subcutaneous 
infection, the virus quickly replicates in the muscle near the sight of inoculation 
and rapidly produces high titer viremia. The virus then targets the central nervous 
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system and brain, where it primarily infects neurons in the hippocampus and the 
anterior horn of the spinal cord, resulting in large scale inflammation and 
encephalitis [78]. At this stage, mice typically develop severe neurological 
symptoms, including paralysis of one or multiple limbs, and experience significant 
weight loss. Death due to encephalitis occurs between 7-9 days post infection for 
5-week old C57BL/6 mice [79]. Severity of disease is dependent on age, as fully 
matured mice do not succumb to disease and do not develop severe neurological 
symptoms [79, 80]. This age-dependent resistance to SINV infection is believed 
to be largely due to the maturation of neurons in the brains and central nervous 
system (CNS). This is reflected in tissue culture models of infection, where SINV 
infection of undifferentiated neurons resulted in high levels of viral replication and 
cell death, while infection of differentiated neurons resulted in low levels of viral 
replication and very little to no cell death [81].  
The ability of mature neurons to resist SINV infection has been linked to 
the expression of a number of proteins, but as of yet, none of have been shown 
to confer complete protection from viral infection. Neuron differentiation has been 
shown to lead to changes in the expression of antiviral genes, and this is at least 
in part due to the increased expression of IRF3 and IRF7 [82]. Interferon 
response factors (IRFs) are transcription factors that activate interferon 
stimulated gene (ISG) expression in response to interferon (IFN) as well as 
induce IFN activation. While both IRF3 and IRF7 likely play important roles in 
enhancing antiviral signaling during infection, they are not solely responsible for 
restriction of viral replication in mature neurons, as silencing IRF7 expression in 
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mature neurons did not restore viral replication to the same levels seen in 
immature neurons. In addition to expressing higher levels of antiviral genes, 
mature neurons also more readily respond to IFN-γ, which activates the 
JAK/STAT signaling pathway and induces the expression of multiple ISGs that 
reduce SINV replication [83, 84]. Another important difference between mature 
and immature neurons is the expression of apoptosis-modulating proteins. In 
particular, Bcl-2 and Bax were found to inhibit SINV-induced apoptosis and their 
expression is correlated with survival [85]. Over expression of the apoptotic 
proteins Bcl-2 and Bax in weanling mice resulted in lower mortality, suggesting 
that they protect neurons associated with survival. However, expression of these 
two proteins did not prevent the death of spinal cord motor neurons or hind limb 
paralysis, indicating that there are other factors at play.  
Viral-induced apoptosis of neurons during infection is thought to be the 
main mechanism by which inflammation is induced in the brain, ultimately leading 
to encephalitis and the death of the host. SINV, as well as the encephalitic 
alphaviruses in general, are thought to induce apoptosis in a number of ways in 
the CNS. One is through the fusion of the viral envelope with the host endosomal 
membrane can trigger apoptosis by activating sphingomyelinase, leading to the 
release of ceramides that induce apoptosis [86]. A second way that SINV may 
induce apoptosis in neurons is by decreasing NA+K+-ATPase activity, resulting 
in the depolarization of the cell membrane and an influx of toxic levels of Ca2+, 
inducing cell lysis [87]. The death of neurons in the brain by viral infection leads 
to the release of pro-inflammatory pathogen- and damage-associated molecular 
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patterns (PAMPs and DAMPs) as well as glutamate. The release of glutamate in 
particular can result in the death of neighboring infected and uninfected neurons. 
Excessive activation of the glutamate receptor leads to an influx of Ca2+, 
inducing excitotoxic cell death, which releases more PAMPs, DAMPs, and 
glutamate, and leads to further bystander death [86, 87]. 
The release of PAMPs and DAMPs from infected cells as well as the 
production of pro-inflammatory cytokines and chemokines results in the 
infiltration of immune cells into the brain, namely macrophages and T-cells [88]. 
In addition to the killing of neurons via direct viral infection, pathogenesis is also 
thought to be the result of excessive inflammation caused by the host antiviral 
immune response, as initiation of viral clearance and the inflammatory response 
correlates with the onset of neurological symptoms [89]. In particular, T-cells are 
thought to play a large role in exacerbating inflammation in the brain and their 
infiltration into the brain has been linked with fatal encephalomyelitis. This 
conclusion comes from studies which showed that mice deficient for αβ T cells 
had increased survival compared to wild type mice when infected with 
neurovirulent SINV [90, 91]. Therefore, controlling the inflammatory response in 
the brain so that viral clearance still occurs without damage to surrounding tissue 
is a critical aspect of determining lethality of encephalitic alphaviral disease.  
Clearance of virus from the brain occurs in a primarily noncytolytic manner 
in order to prevent further damage to neural tissue. This process is largely 
mediated by IFNγ produced from T cells as well as antibodies produced by B-
cells against the viral glycoproteins [92, 93]. In particular, the B-cell production of 
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antibodies which suppress viral infection is important for continued clearance of 
virus, as the viral RNA can persist in neurons for years following infection and 
has been shown to be capable of reactivating viral replication in mice deficient of 
B-cells [84, 94, 95].  
 
Alphaviral Pathogenesis Traits 
 Using both cellular and animal models of alphaviral disease, several key 
determinants of alphaviral pathogenesis have been identified. These virulence 
traits span both the viral proteins and the viral RNAs themselves and serve to 
both evade the induction of and blunt the efficacy of the innate immune response 
to infection. As the alphaviruses are highly sensitive to the effects of the Type-I 
IFNs, evading the host innate immune response is critical to alphaviral infection 
and pathogenesis. This section will detail the known alphavirus virulence traits.  
 
Virulence Traits of the Nonstructural Proteins 
In addition to its roles during alphaviral replication, the nsP1 protein is 
known to be important for alphaviral pathogenesis and multiple residues in nsP1 
have also been identified as determinants for alphaviral virulence. In particular, 
palmitoylation of nsP1 is known to be important for viral pathogenesis as 
mutations in nsP1 that prevented palmitoylation were also found to impact 
neurovirulence in mice. Specifically, when the palmitoylated residues in nsP1 
were mutated to alanine in Semliki Forest Virus (SFV), was found to replicate in 
mice and produce viremia but would no longer traffic to the brain and completely 
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ablated mortality [96]. Apart from palmitoylation, a set of six mutations in nsP1 of 
RRV was found to attenuate viral infection in mice due to reduced viral replication 
in specific tissues. More specifically, RRV with these 6 nsP1 mutations was 
found to have decreased replication in the skeletal muscle tissue and was more 
sensitive to type I IFN [97, 98]. In addition to altered pathogenesis in vivo, the 
RRV nsP1 mutant was also shown to have decreased production of noncapped 
genomic RNA during viral replication; however, how this may have contributed to 
the virus’s attenuation in vivo was unknown [99]. Finally, cleavage of nsP1 from 
nsP2 has also been identified to be a major determinant of virulence. The SINV 
T538I mutation in nsP1 is known to affect virulence by altering processing of the 
nonstructural polyprotein and the virus’s sensitivity to interferon. The substitution 
of isoleucine for threonine at position 538 in nsP1 was found to decrease the 
speed of polyprotein processing and significantly affect neurovirulence [100, 
101]. Mice infected with the SINV that had a threonine at position 538 developed 
severe neurological symptoms and high mortality rates. In contrast, those 
infected with SINV that had an isoleucine at position 538 only experienced mild 
disease and no mortality [102]. This has been attributed to the altered viral 
sensitivity to IFN due to the slowed processing of nsP2 preventing it from 
inhibiting the JAK-STAT signaling pathway. 
 nsP2 is known to play several roles apart from its involvement in viral 
replication which are critical for alphaviral pathogenesis. This includes inhibiting 
the JAK-STAT signaling pathway mentioned above, which is a major means by 
which production of antiviral effectors is induced. Binding of IFN to the IFN 
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receptor results in the autophosphorylation of the associated kinases JAK1 and 
Tyk2 for the type I IFN receptors or JAK1 and JAK2 for the type II IFN receptors. 
The kinases in turn then phosphorylate the IFN receptor, which leads to the 
recruitment of the STAT proteins. The STAT proteins are then phosphorylated 
and released as dimers that then go to the nucleus to activate the transcription of 
interferon stimulated genes (ISGs). During alphaviral infection, nsP2 inhibits this 
pathway by disrupting the translocation of STAT1 to the nucleus, thus preventing 
STAT1 from binding to the DNA and inducing transcription of ISGs [103, 104]. As 
stated previously, the inhibition of the JAK-STAT pathway is known to be 
important for virulence, as the T538I mutation in nsP1 which alters this activity of 
nsP2 results in decreased pathogenesis. In addition to inhibiting the JAK-STAT 
pathway, nsP2 is also known to be responsible for host shutoff. In the 
arthritogenic alphaviruses, shutoff of host transcription occurs through 
translocation of nsP2 to the nucleus, where it induces degradation of RNA 
polymerase II subunit RPB1 [45]. nsP2 is also thought to play an important role in 
the shutoff of host translation as well, although the exact mechanism is not yet 
understood [105]. Host shutoff has been linked to viral cytopathogenicity, as a 
P726G mutation in nsP2 which prevents shutoff of host transcription results in 
decreased cell death and viral persistence in mammalian cells in vitro [106].  
 In addition to inhibiting host immunity, transcription, and translation, 
modulating the host stress response is also an important aspect of alphaviral 
infection. Viral infection can trigger the formation of stress granules within the 
host, resulting the in the sequestration of host translation machinery and an 
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arrest in both host and viral protein synthesis. Alphaviruses are known to 
suppress stress granule formation through the ADP-ribosylhydrolase activity of 
nsP3 [47]. By removing ADP-ribose from ADP-ribosylated proteins present in 
stress granules, nsP3 is able to disassemble the stress granules that form in 
response to infection. This activity of nsP3 is known to be important for efficient 
viral replication and thus for pathogenesis as well. Mutations in nsP3 of CHIKV 
which abolish hydrolase activity results in virus that is unable to replicate in either 
mammalian or mosquito cells. Similarly, reducing the nsP3’s ability to bind ADP-
ribose results in slower viral replication in tissue culture as well as significantly 
reduced mortality in 2-day old mice, illustrating the importance of nsP3 ADP-
ribosylhydrolase activity to alphaviral virulence [107]. 
 
Virulence Traits of the Structural Proteins 
 There have also been several virulence determinants identified in the 
structural proteins in addition to the nonstructural proteins. In the encephalitic 
alphaviruses, capsid is responsible for shutoff of host transcription rather than 
nsP2. In contrast to the arthritogenic viruses, shutoff of host transcription by the 
encephalitic alphaviruses utilizes capsid, which blocks nucleocytoplasmic 
trafficking in the host cell [108]. Similar to what occurs in the arthritogenic 
alphaviruses, host shutoff of transcription by the encephalitic alphaviruses is also 
associated with cytopathogenicity, as mutations in capsid which prevent host 
shutoff also results in decreased cell death [109]. In addition to the capsid 
protein, the viral glycoproteins have also been shown to be important for 
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virulence, particularly in regard to viral entry. There are multiple residues in the 
viral glycoproteins that are known to affect disease severity. In SINV, 
development of neurovirulence has been specifically association with mutations 
in E1 and E2, which are responsible for membrane fusion and receptor binding 
respectively [110]. Mutations in the glycoproteins have also been shown to affect 
host range, tissue/cell tropism, cell attachment, and immunogenicity [111-114]. 
 
Virulence Traits of the Alphavirus RNAs 
In addition to the above protein-based virulence traits, there are multiple 
features of the viral RNA that have been characterized as key determinants of 
alphaviral virulence. Several contribute to viral infection by preventing detection 
of the viral RNA by innate immune sensors. A major way that the host cell 
differentiates self from non-self RNA is through the addition of a modified cap 
structure to the 5’ end of mRNA. In particular, RIG-I detects RNA in the 
cytoplasm which have a 5’ tri- or diphosphate instead of the proper cap structure. 
Once RIG-I binds to a noncapped RNA, it interacts with MAVS and starts a 
signaling cascade which leads to the induction of type I IFN. In order to avoid 
detection by RIG-I, alphaviruses add a type 0 cap to the 5’ ends of the vRNA. 
However, this cap differs from the host type 1 cap in that it is not 2’O methylated. 
RNA that lack the 2’O methylation of the 5’ cap can be sensed by IFIT1, which 
can bind to the RNA and block translation. To avoid detection by IFIT1, 
alphaviruses have a stable stem-loop in the 5’UTR which prevents IFIT1 from 
binding the vRNA [115]. This structure has been shown to be important for 
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virulence in multiple alphaviruses as disruption of the stem-loop with point 
mutations in the 5’UTR, especially at nucleotides 3, 5, and 8, results in 
attenuated neurovirulence in mice [115-118]. 
 In addition to the viral cap structure and secondary structure in the 5’UTR, 
the Opal stop codon between nsP3 and nsP4 is also a determinant for alphaviral 
virulence. However, how the Opal stop codon impacts viral pathogenesis 
changes depending on the alphavirus. Mutation of the opal stop codon in CHIKV 
results in reduced pathogenicity as mice infected with virus where the Opal 
codon has been replaced with arginine experience decreased footpad swelling 
and reduced inflammation in the joint [119]. In contrast, introduction of the opal 
stop codon in SFV lead to significant attenuation of disease in adult mice [120]. 
There is also some evidence that the importance of the Opal stop codon to 
virulence may be dependent on the host. In O’nyong’nyong virus (ONNV), the 
presence of the Opal stop codon results in increased viral replication in BHK 
cells, but drastically decreased replication in C6/36 mosquito cells [121]. While 
the mechanism by which the Opal stop codon impacts virulence has not been 
characterized, it is thought to play a role in controlling the amount of nsP4 which 
is produced [122]. 
 
Noncapped Genomic Alphaviral RNA 
While capping of the genome is crucial for viral replication, alphaviral RNA 
are not universally capped and the rate at which the vRNA is capped changes 
depending on the host. Furthermore, both capped and noncapped vRNA are 
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packaged into viral infection, despite the fact that the noncapped genomes 
cannot be translated and are essentially noninfectious [99]. During vertebrate 
infection, SINV produces and packages approximately four-fold more noncapped 
genomic RNA (ncgRNA) than capped genomic RNA (Fig. 1.4A). In contrast, 
SINV infection of mosquito produces capped and ncgRNA in approximately equal 
parts. Additionally, it is known that different amounts of ncgRNA are produced at 
different points during infection. More specifically, in mammalian tissue culture 
models of infection, capping efficiency improves and ncgRNA production 
decreases as infection progresses (Fig. 1.4B). Regardless, this overwhelming 
presence of ncgRNA during viral infection suggests that they play an important 
role in alphaviral infection. While the specifics of what the ncgRNA do during 
infection are poorly understood, they are known to be important for proper viral 
infection. As mentioned in the previous section, a RRV mutant that was 
attenuated in mice was found to produce less ncgRNA compared to the WT RRV 
[97, 99]. Additionally, the presence of the ncgRNA during infection of mammalian 
cells is known to be correlated with the activation of type I interferon [99]. 
Noncapped genomic RNA are also known to be important for alphaviral infection 
of mosquitos, as particles that contained primarily ncgRNA where able to more 
efficiently initiate infection in the midgut than those containing capped genomic 
RNA [123].  
Altogether, these findings suggest that the production of ncgRNA is linked 
to alphaviral infection and pathogenesis. However, there has yet to be a study 
which directly links ncgRNA production to the virus’s ability to replicate and 
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produce disease. This is partially due to the lack of a good system by which 
ncgRNA production can be reliably altered for the entire course of infection. 
Mackenzie-Liu et al where able to separate particles containing capped RNA 
from those containing ncgRNA by density, as the capped RNA correlated with 
heavier particles. However, this method only changes the proportion of capped 
and ncgRNA present during the initial round of viral infection, as the ratios of 
capped to ncgRNA will return to wild type after one round of replication. Thus, 
one of the primary goals of this project was to establish a means by which 
ncgRNA production could be altered that would last for the entirety of infection.  
 Characterization of residues in nsP1 that impact vRNA capping have 
largely focused on residues that abolish either the methylatransferase or 
guanylyltransferase activities of nsP1. Mutation of these residues is lethal to the 
virus, making them unsuitable for studying the functions of ncgRNA during viral 
infection. However, in 2015 a study by Li et al reported a number of resides in the 
nsP1 of VEEV that, when mutated, where capable of decreasing or increasing 
cap formation to various degrees. Among them, alanine substitutions at positions 
285 and 375 decreased capping efficiency by ~10 and 2 fold respectively 
compared to wild type nsP1. Additionally, an alanine substitution at the 354 
position increased capping efficiency by ~3.5 fold [124]. This was the first time 
that it was shown that it was possible to increase the capping activity of nsP1. 
The Y285, N375, and D354 residues in VEEV are very highly conserved among 
both the arthritic and encephalitic alphaviruses, making it likely that mutation of 
these residues in other alphaviruses will result in a similar effect on capping 
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efficiency. Additionally, all three of these residues occur at interesting locations in 
the recently described structure of nsP1 (Fig 1.5). The Y285 residue falls within 
the capping domain of nsP1 and is known to be involved in binding GTP for 
methylation. While the specific location of the N375 residue has not been 
resolved, both it and the D354 residue occur in structures that extend out from 
the waist of the enzyme and into the pore formed by the nsP1 ring [33]. It is worth 
noting that it is currently unknown whether nsP1 is enzymatically active when 
forming the ring complex, therefore the location of the N375 and D354 residues 
within the structure of nsP1 may differ when nsP1 is active and part of the 
replication complex. Overall, the location of these residues in nsP1, their highly 
conserved nature, and their ability to affect nsP1 capping efficiency, and 
therefore ncgRNA production, made the Y285A, N375A, and D354A mutations in 
particular good candidates for determining the importance of ncgRNA to 
biological infection.  
 
Rationale 
Alphaviruses are known to produce significant quantities of viral genomic RNAs 
that lack the canonical viral 5’ cap structure. These noncapped genomic RNA are 
known to be packaged into viral particles, despite the fact that the noncapped 
genomes cannot be translated and are essentially noninfectious [99]. 
Furthermore, previous studies suggest that ncgRNA production may be a 
determinant of alphaviral pathogenesis [97, 99]. While these findings suggest 
that the ncgRNA are important for alphaviral infection, the role that the ncgRNA 
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play during viral infection and the development of viral pathogenesis had yet to 
be characterized. This led to the hypothesis that the ncgRNAs were critical to 
efficient alphaviral infection and the development of pathogenesis. To determine 
the role of the ncgRNA during alphaviral infection, we developed a set of nsP1 
mutants in SINV that had either increased or decreased RNA capping efficiency, 
which would lead to consistently altered ncgRNA production during infection. We 
then used these nsP1 capping mutants to characterize the impact of altered 
ncgRNA production on viral infection at the molecular level in cellular models of 
infection (Chapter 2) as well as on viral pathogenesis using animal models of 
infection (Chapter 3). Defining the role of the ncgRNA during alphaviral infection 
will not only expand our knowledge by characterizing a novel alphaviral RNA 
species, but will also give insight to the development of novel antiviral strategies 





Figure 1.1. Alphaviral transmission and disease. The natural transmission 
cycle of alphaviruses is between an invertebrate vector and a vertebrate host. 
Epizootic spillover events can occur that results in the infection of humans. Once 
the virus is transmitted from the mosquito vector to a human host, the virus 
begins to replicate resulting in high titer viremia as well as febrile illness and 
rash. Depending on the alphavirus, the disease then has the potential to develop 
into either potentially lethal encephalitis or debilitating arthritis. Examples of 
encephalitic alphaviruses include VEEV, WEEV, and EEV, while the arthritogenic 






Figure 1.2. The alphaviral life cycle. 1) Alphaviral infection begins with the viral 
particle binding to receptors on the surface of the host cell and entering via 
receptor mediated endocytosis. 2) After entry, the viral envelope fuses with the 
endosomal membrane leading to release of the nucleocapsid core, which is then 
disassembled to release the viral genome. 3) The viral genome is then translated 
to produce the nonstructural proteins, which are processed to form the viral 
replicase. The viral replicase then synthesizes the negative strand RNA template 
as well as the subgenomic RNA. The subgenomic RNA is then translated to 
produce the structural proteins, which include the glycoproteins and capsid. 4) 
The glycoproteins are processed in the endoplasmic reticulum and then trafficked 
to the cell surface. 5) Capsid associates with the newly synthesized genomic 
RNA to form the nucleocapsid core. 6) Newly formed viral particles are released 




Figure 1.3. Alphaviral RNA replication and genetic organization. Translation 
of the viral genome produces the nonstructural polyprotein P1234. nsP4 is first 
cleaved off and associated with P123 in order to form the complex that is 
responsible for synthesizing the minus strand RNA template. P123 is then further 
processed into the individual nonstructural proteins nsP1, 2, and 3. The four fully 
processed nonstructural proteins then form the replication complex that is 






Figure 1.4. Capped and noncapped genomic RNA are produced during 
alphaviral infection. (A) Quantitative assessment of the 5’ terminus of 
encapsidated SINV genomic RNAs from particles produced during infection of 
mammalian (BHK-21) and mosquito (C6/36) tissue culture cells. (B) Quantitative 
assessment of the encapsidated SINV genomic RNAs from particles produced in 
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the mammalian 293HEK tissue culture cell line over time. Data shown are the 
means of at least 3 independent replicates, with error bars representing the 






Figure 1.5. Structure of nsP1. Amino acid residues of importance are 






INCREASING THE CAPPING EFFICIENCY OF THE SINDBIS VIRUS NSP1 
PROTEIN NEGATIVELY AFFECTS VIRAL INFECTION1 
 
Summary 
Alphaviruses are arthropod-borne RNA viruses that are capable of 
causing severe disease and are a significant burden to public health. Alphaviral 
replication results in the production of both capped and noncapped viral genomic 
RNAs, which are packaged into virions during the infections of vertebrate and 
invertebrate cells. However, the roles that the noncapped genomic RNAs 
(ncgRNAs) play during alphaviral infection have yet to be exhaustively 
characterized. Here, the importance of the ncgRNAs to alphaviral infection was 
assessed by using mutants of the nsP1 protein of Sindbis virus (SINV), which 
altered the synthesis of the ncgRNAs during infection by modulating the protein’s 
capping efficiency. Specifically, point mutants at residues Y286A and N376A 
decreased capping efficiency, while a point mutant at D355A increased the 
capping efficiency of the SINV genomic RNA during genuine viral infection. Viral 
growth kinetics were significantly reduced for the D355A mutant relative to wild 
 
1 This chapter is adapted from work published in mBio, 2018, Volume 9, Issue 6 with the same 
title under a Creative Commons Attribution (CC BY) license 125. LaPointe, A.T., et al., The 




type infection, whereas the Y286A and N376A mutants showed modest 
decreases in growth kinetics. Overall genomic translation and nonstructural 
protein accumulation was found to correlate with increases and decreases in 
capping efficiency. However, genomic, minus strand, and subgenomic viral RNA 
synthesis was largely unaffected by the modulation of alphaviral capping activity.  
In addition, translation of the subgenomic vRNA was found to be unimpacted by 
changes in capping efficiency. The mechanism by which decreased presence of 
ncgRNAs reduced viral growth kinetics was through the impaired production of 
viral particles. Collectively, these data illustrate the importance of ncgRNAs to 




 Alphaviruses are positive sense, single-stranded RNA viruses which are 
capable of being transmitted between sylvatic vertebrate reservoir hosts and 
competent mosquito vectors in an enzootic cycle. During epizootic events, these 
viruses are capable of causing severe disease and are broadly categorized into 
two groups based on symptomology. Disease caused by the encephalitic 
alphaviruses, such as Venezuelan Equine Encephalitis virus, are characterized 
by neurological symptoms and are capable of causing severe encephalitis, which 
may result in the death of the vertebrate host [11, 12]. In contrast, the 
arthritogenic alphaviruses, such as Sindbis virus (SINV), Ross River virus (RRV), 
and Chikungunya (CHIKV), cause disease ranging in severity from mild febrile 
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illness to debilitating polyarthritis, which may persist for several months to years 
past the acute phase of infection [3, 5, 126-128]. Despite the burden to public 
health posed by the alphaviruses, there are currently no effective and safe 
antiviral treatments for alphaviral disease.   
During alphaviral infection, three viral RNA species are produced: the 
genomic strand, which encodes the nonstructural polyprotein, which is processed 
proteolytically to form the replication machinery; a minus strand RNA template; 
and a subgenomic RNA, which encodes the structural proteins. The positive 
sense alphaviral RNAs (vRNAs), namely the genomic and subgenomic vRNAs, 
have a type-0 cap structure co-transcriptionally added to their 5’ ends during 
RNA synthesis in order to protect the 5’ end of the transcript and to facilitate 
translation after entry to the host cell [129-131]. The addition of the 5’ cap 
structure to the positive sense vRNAs is a multistep process involving at least 
two alphaviral nonstructural proteins. Briefly, the methyltransferase domain of the 
alphaviral nsP1 protein catalyzes the addition of a methyl group from S-
andenosylmethionine to a GTP molecule, forming a covalent m7GMP-nsP1 
intermediate [132]. Following the removal of the 5’ γ-phosphate on the nascent 
vRNA molecule by nsP2, the m7GMP moiety is then transferred to the vRNA 
molecule by the guanylyltransferase activities of nsP1, resulting in the formation 
of the type-0 cap structure, 7meGpppA [40, 133]. Importantly, biochemical studies 
of alphaviral nsP1 proteins have found that both the methyltransferase and 
guanylyltransferase activity of nsP1 can be altered either negatively or positively 
via point mutations in vitro [35, 124, 134].   
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The presence of the type-0 cap structure on the alphaviral genomic and 
subgenomic vRNAs were first observed by paper electrophoresis, or thin-layer 
chromatography, of metabolically labeled vRNAs that were chemically and 
enzymatically degraded [129, 130, 135]. These studies further identified the 
sequences of the 5’ termini of the alphaviral genomic and subgenomic vRNAs, 
which provided the first evidence for independent promoter initiation for the two 
positive-sense vRNA species [130]. While these studies were able to identify the 
presence of the 5’ type-0 cap structure, they were, by the nature of their design 
and technological limitations, unable to determine the relative frequency with 
which the positive sense vRNAs were capped.  
Recently, we reported findings that indicated that the alphaviral genomic 
vRNAs are not ubiquitously capped, and that a significant proportion of the 
genomic vRNAs produced during SINV and RRV infection lack the 5’ type-0 cap 
structure [99]. Furthermore, analyses of infectious and noninfectious viral 
particles demonstrated that both the capped and noncapped genomic vRNAs are 
packaged into viral particles throughout the course of infection. Through the use 
of tissue culture models of alphaviral infection, the presence of the noncapped 
vRNAs were found to correlate with the activation of a type-I IFN response. 
Moreover, an attenuated RRV mutant was found to produce fewer noncapped 
genomic RNAs relative to wild type virulent RRV [97, 99]. Collectively, these data 
were highly suggestive of an important biological role for the noncapped genomic 
vRNAs during infection; however, the precise functions of the noncapped 
genomic vRNAs during infection remained unknown.  
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The goal of this study was to determine the importance of noncapped 
vRNAs to SINV infection of tissue culture cells. Here, we show that the capping 
activity of SINV nsP1 is capable of being modulated, both positively and 
negatively, via the mutation of specific residues within the Iceberg Domain, a 
structurally organized domain of cryptic function that is conserved amongst many 
viral capping enzymes (12). In addition, SINV infection was determined to be 
more detrimentally impacted by increasing the capping efficiency of SINV nsP1, 
rather than by decreasing efficiency. Specifically, increasing the rate of alphaviral 
capping negatively impacts viral growth kinetics by negatively affecting viral 
particle production. Collectively, our findings indicate that the noncapped vRNAs 
do play an important role during viral infection, and that decreasing the presence 
of noncapped vRNA impacts the viral life cycle at a fundamental level.  
 
Materials and Methods 
 
Tissue Culture Cells 
Baby hamster kidney 21 (BHK-21) fibroblast cells (a gift from R.W. Hardy, 
Indiana University- Bloomington) were maintained in Minimal Essential Media 
(MEM, Cellgro) containing 10% fetal bovine serum (FBS, Atlanta Biologicals), 1% 
antibiotic-antimycotic solution (Cellgro), 1% nonessential amino acids (Cellgro), 
and 1% L-glutamine (Cellgro). Cells were cultured at 37°C and at 5% CO2 in a 
humidified incubator. Low passage stocks were maintained via regular passaging 




Generation of SINV Capping Mutants 
The SINV nsP1 mutants used in this study were generated either by site 
directed mutagenesis, or Gibson assembly reactions. Particularly, the SINV p389 
Y286A and D355A mutants were generated via site-directed mutagenesis 
according to the instructions for Q5 site-directed mutagenesis kit (NEB). To this 
end, the parental wild type strain consisting of the p389 SINV nsP3-GFP reporter 
strain was PCR amplified with high fidelity Q5 DNA polymerase using primer sets 
that incorporated the indicated alanine substitutions, individually. Due to technical 
limitations that prevented the successful use of site-directed mutagenesis, the 
N376A mutant was generated by Gibson assembly via the Gibson Ultra kit (SGI) 
through the use of restriction digested p389 cDNA plasmid and a synthetic DNA 
fragment, according to the manufacturers’ instructions. SINV nanoluciferase 
reporters mutants, similar to those previously described, were generated by 
either site-directed mutagenesis, or by conventional restriction enzyme cloning 
schemes which swapped the GFP coding region of the existing p389 site 
mutants with a Nanoluciferase coding region in a modular fashion [99].  
In all cases, individual mutants were verified by whole genome 
sequencing before proceeding to subsequent analyses. Full genome sequences 
are available upon request. Highly similar phenotypes were observed for any 
given mutant in all virus backgrounds evaluated.  
 
Production of SINV Wild Type and Mutant Virus Stocks  
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Wild type, Y286A, D355A, and N376A SINV p389 (a derivative of the 
Toto1101 strain containing GFP in frame with nsP3 [136]), as well as SINV 
pToto1101-nanoluc (a derivative of the Toto1101 strain containing nanoluciferase 
in frame with nsP3 [99]), were prepared by electroporation as previously 
described [125, 137]. Briefly, 2.8x106 BHK-21 cells were electroporated with 
10μg of in vitro transcribed RNA using a single pulse at 1.5kV, 25mA, and 
200Ohms from a Gene Pulser Xcell system (BioRad) as previously described 
[125]. Cells were then incubated at normal incubation conditions until cytopathic 
effect became apparent, at which point the supernatant was collected and 
clarified by centrifugation at 8,000xg for 10min at 4oC. The clarified supernatant 
was then aliquoted into small-volume stocks, which were then stored at -80oC for 
later use. 
 
Analysis of Viral Growth Kinetics 
To determine if mutation of the SINV nsp1 protein negatively affected 
infection, the viral growth kinetics of each of the individual strains described 
above were assayed in tissue culture models of infection. Essentially, BHK-21 
cells were seeded in a 24-well plate and incubated under normal conditions. 
Once cell monolayers were 80-90% confluent, they were infected with either the 
wild-type parental virus, or the individual capping mutant viruses, at an MOI of 5 
infectious units (IU) per cell. After a 1hr adsorption period, the inoculum was 
removed and the cells were washed twice with 1x PBS to remove unbound viral 
particles. Whole media was added, and the cells were incubated at 37⁰C in a 
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humidified incubator in the presence of 5% CO2. At the indicated times post 
infection, tissue culture supernatants were harvested (and the media replaced), 
and viral titer was determined via plaque assay.  
 
Quantification of Infectious Virus by Plaque Assay 
Standard virological plaque assays were used to determine the infectious 
titer of all viral samples produced during these studies. Briefly, BHK-21 cells were 
seeded in a 24-well plate and incubated under normal conditions. Once the cell 
monolayers were 80-90% confluent, they were inoculated with 10-fold serial 
dilutions of virus-containing samples. After a 1hr adsorption period, cells were 
overlaid with a solution of 0.5% Avicel (FMC Corporation) in 1x media for 28-
30hrs [138]. The monolayers were fixed with formaldehyde solution (3.8% 
formaldehyde in 1xPBS) for a period of no less than one hour. Plaques were 
visualized via staining with crystal violet after removal of the overlay and 
quantified by manual counting.  
 
XRN1 Protection Assay/ RppH Assay 
 Viral genomic RNAs were extracted from purified viral particles harvested 
at 24hpi. After extraction, the RNA samples were subjected to enzymatic 
degradation via the 5’3’ exonuclease XRN-1, which is capable of degrading 5’ 
monophosphate and RNAs in vitro, but is unable to effectively degrade RNA 
substrates that are 5’ capped [139, 140]. Briefly, equivalent amounts of viral 
genomic RNAs were incubated in the presence of 0.25 units of XRN-1 in a final 
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volume of 20μl for a period of 5 minutes at 37° prior to being quenched via the 
addition of High Salt Column Buffer (25mM Tris-HCl, pH 7.6 / 400mM NaCl / 
0.1% w/v Sodium Dodecyl Sulfate (SDS). After the termination of the reaction, 
the RNAs were purified via phenol:chloroform extraction and ethanol precipitation 
with linear acrylamide carrier. The resulting precipitate was resuspended and 
utilized as the substrate for the synthesis of cDNA via ProtoScript II reverse 
transcriptase (NEB). The resulting cDNAs were quantified via qPCR of an 
amplicon located in the nsP1 region, as described below, to determine the 
sensitivity of a sample relative to wild type viral genomic vRNAs [125, 141].  
 To confirm that the nature of the 5’ end, in particular the presence of a 5’ 
cap structure, was responsible for the differences in XRN-1 sensitivity the 
extracted RNAs were co-incubated with XRN-1 in the presence of the decapping 
enzyme RppH [99, 142, 143]. To this end, the above reactions were 
supplemented with 1.25 units of RppH and processed as described above.  
 
Metabolic Labeling of Protein Synthesis 
To determine the rates of host and viral during infection, BHK-21 cells 
were seeded in a 12-well tissue culture dish and grown to 80-90% confluence 
prior to being infected with either wild type parental virus, or one of the individual 
capping mutant viruses at an MOI of 10 IU/cell. After a 1hr adsorption period, 
fresh media was added to each well, and the cells were incubated under their 
normal incubation conditions. Thirty minutes before the indicated times post 
infection, the media was removed and replaced with methionine- and cysteine-
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free DMEM (Cellgro) to starve the cells of methionine. After a 30 minute 
incubation period, the starvation media was removed and replaced with 
methionine- and cysteine-free DMEM supplemented with 50μM L-
azidohomoalanine (L-AHA), a methionine analogue [144, 145]. After 2hrs, the 
labeling media was removed, the cells were washed with 1x PBS, and then 
harvested with RIPA buffer (50mM Tris-HCl, pH 7.5 / 150mM NaCl / 1% v/v 
Nonidet P-40 (NP-40) / 0.5% w/v SDS / 0.05% w/v Sodium Deoxycolate / 1mM 
EDTA). Cell lysates were labelled with DIBO-Alexa 648 (Invitrogen) at a final 
concentration of 5μM and incubated at room temperature in the dark for at least 1 
hour. The labeled lysates were then loaded onto a 12% SDS-PAGE gel, and the 
proteins were separated by electrophoresis. Fluorescence was then imaged 
using a Pharos FX Plus Molecular Imager (BioRad), and densitometry of 
individual protein species was used to quantify viral and host protein expression. 
 
Western Blot Detection of SINV nsP2 Protein Expression 
 Whole cell lysates were generated from BHK-21 cells infected with either 
wild type, or individual SINV nsP1 capping mutant viruses by resuspension in 
RIPA buffer at 12 and 16hpi. Equivalent amounts of protein were loaded onto 
10% acrylamide gels, and the individual protein species were resolved using 
standard SDS-PAGE practices. After sufficient resolution of the protein species, 
the proteins were transferred to PVDF membranes, which were rinsed in 
methanol and thoroughly dried after transfer. After drying the blots were probed 
with anti-SINV nsP2 polyclonal sera (a gift from R.W. Hardy at Indiana 
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University- Bloomington), or anti-Actin (clone mAbGEa, ThermoFisher Scientific) 
antibodies diluted in 1xPBS supplemented with 1.0% v/v Tween (PBST) for a 
period of at least one hour at 25ºC under gentle rocking. The blots were washed 
three times with 1xPBST, and probed with fluorescent anti-rabbit (A32732, 
ThermoFisher Scientific) and anti-mouse secondary (A32723, ThermoFisher 
Scientific) antibodies. Protein detection was achieved using a Pharos FX Plus 
Molecular Imager (BioRad), and densitometry of individual protein species was 
used to quantify viral and protein expression. 
 
qRT-PCR Detection of SINV vRNAs 
The quantitative detection of the SINV vRNAs was accomplished as 
previously described, with minor modifications [137]. Briefly, to quantify the SINV 
genomic, subgenomic, and negative sense vRNAs, BHK-21 cells were infected 
at an MOI of 5 IU/cell and cells were harvested at 2, 4, and 8hpi via the addition 
of Ribozol (VWR). Total RNA was then isolated via extraction, and 1μg was 
reverse transcribed using Protoscript II Reverse Transcriptase (NEB) and a 
cocktail of specific RT primers based on the intended amplification targets. To 
detect the positive-sense RNA species the RT primer cocktail consisted of nsP1, 
E1, and 18S reverse primers; and to detect the minus strand the RT cocktail 
consisted of nsP1 forward and 18S reverse primers. The individual vRNA 
species were detected via TaqMan probes using the following primer sets: SINV 
nsP1 F 5’-AAGGATCTCCGGACCGTA-3’, SINV nsP1 R 5’-
AACATGAACTGGGTGGTGTCGAAG-3’; SINV E1 F 5’-
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TCAGATGCACCACTGGTCTCAACA-3’, SINV E1 R 5’- 
ATTGACCTTCGCGGTCGGATACAT-3’; Mammalian 18S F 5’- 
CGCGGTTCTATTTTGTTGGT-3’, Mammalian 18S R 5’- 
AGTCGGCATCGTTTATGGTC-3’. The sequences of the TaqMan detection 
probes are as follows: SINV nsP1 Probe 5’-
ACCATCGCTCTGCTTTCACAACGA-3’, SINV E1 Probe 5’- 
ACTTATTCAGCAGACTTCGGCGGG-3’, and Mammalian 18S Probe 5’- 
AAGACGGACCAGAGCGAAAGCAT-3’. 
 To quantify the total number of viral particles present in a sample, BHK-
21 cells were infected at an MOI of 5 IU/cell and supernatant was collected at 
24hpi. As previously described, 5uL of supernatant was reverse transcribed 
[137]. Reverse transcription and qPCR reactions were performed identical to 
those above with the exception of the mammalian 18S primer and probes not 
being used. Absolute quantities of viral genomic RNAs were determined via the 
use of a standard curve of known concentration. To determine the amount of 
subgenomic vRNA present, the absolute quantities of RNA detected with the 
nsP1 primer set were subtracted from that detected with the E1 primer set, as the 
E1 primer set will detect both the genomic and subgenomic RNAs, but the nsP1 
primer set will only detect the genomic RNA. 
 
Cell Viability Assay 
To determine the effect of SINV infection on cell viability, BHK-21 cells 
were seeded in a 96-well plate and were infected with the wild type parental virus 
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or the individual capping mutant viruses at an MOI of 10 IU/cell. After a 1hr 
adsorption period, whole medium was added and the cells were incubated under 
normal incubation conditions for the described times. Afterwards, the cells 
washed with 1x PBS and a solution of 1/6th CellTiter 96 AQueous One Solution 
Reagent (Promega) in 1x PBS was added to each well. The cells were then 
allowed to incubate at 37oC and 5% CO2 for 2hrs. Absorbance at 490nm was 
then recorded using a Synergy H1 microplate reader (BioTek).  
 
Quantification of Viral Gene Expression via Nanoluciferase Assays 
To quantify genomic translation during infection, BHK-21 cells were 
infected at an MOI of 5 IU/cell with the wild type parental virus or the individual 
capping mutants containing the nanoluciferase gene within the nsP3 protein [99]. 
After a 1hr adsorption period on ice, the inoculum was removed and the medium 
was replaced with pre-warmed whole medium. The infected cells were incubated 
under normal conditions, and at the indicated times post-infection, the medium 
was removed and the tissue culture cells were washed with 1x PBS. The cells 
were then harvested into a crude lysate by the addition of 1x PBS supplemented 
with 0.5% (v/v) Triton X-100. The lysate was transferred to a microfuge tube and 
frozen until the completion of the experimental time course. The samples were 
thawed and clarified by centrifugation at 16,000Xg for 5 minutes, and equal cell 
volumes of the nanoluciferase samples were processed using the Nano-Glo 
nanoluciferase assay system (Promega) according to the manufacturer’s 
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instructions. Luminescence was then recorded using a Synergy H1 microplate 
reader (BioTek).  
 
Statistical Analysis 
The quantitative data reported in this study are the means of a minimum of 
three independent biological replicates, unless specifically noted otherwise. The 
growth curve data presented in Fig. 2.2 were statistically assessed using an area 
under the curve approach to determine differences in viral growth kinetics 
throughout the course of the assay. The statistical analysis of comparative 
samples was performed using variable bootstrapping where appropriate, as 
previously described [137]. The error bars indicate the standard deviation of the 
mean. The P values associated with individual quantitative data sets are the 
result of Student’s t test for the corresponding quantitative data. 
 
Results 
SINV vRNA Capping Can be Modulated by Point Mutations in the nsP1 
Protein 
As described above, we recently reported that a significant number of 
SINV genomic vRNAs produced during infection lack the type-0 5’ cap structure. 
Despite being noninfectious, the noncapped viral genomic RNAs (ncgRNAs) are 
produced in a temporally dependent manner and are packaged into viral particles 
throughout the course of infection [99]. Given the evolutionary conservation of 
the production of the ncgRNAs during alphaviral infection, we hypothesized that 
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they must be biologically important to viral infection. This led us to question how 
modulating capping activity, which would alter the production of capped viral 
genomic RNAs and ncgRNAs, impacts viral infection. In order to determine the 
biological importance of the ncgRNAs during viral infection, we modulated the 
methyltransferase and guanylyltransferase activities of the alphaviral nsP1 
protein to generate mutant SINV strains with either increased or decreased rates 
of viral capping. These mutations were based on previous work done in VEEV by 
Li et al. (2015), where alanine substitutions at specific residues affected the nsP1 
protein’s methyltransferase and guanylyltransferase activities, as well as cap 
formation as a whole. Specifically, the previous study found that alanine 
substitutions at Y286 and N376 decreased RNA capping efficiency, although to 
different extents, whereas an alanine substitution at D355 increased RNA cap 
formation. All three residues are highly conserved across multiple alphaviruses, 
including the model alphavirus SINV (Fig. 2.1A). Modeling of the SINV nsP1 
protein using ITASSER indicates that residues D355 and N376 are likely close to 
one another, in parallel alpha helices proximal to the catalytic site within the 
Iceberg Domain (Fig. 2.1B)[146]. Nonetheless, Y286 is located at a distal site far 
from the putative active sites, as identified by prior mutational analyses [35, 132, 
133]. Admittedly, the ITASSER predicted structure is unlikely to be a wholly 
accurate representation of the true structure of the SINV nsP1 protein. Despite 
the inherent inaccuracy of protein folding prediction algorithms in the absence of 
a closely related crystal structure, secondary and tertiary structural elements 
reminiscent of methyltransferase and guanylyltransferase enzymes may be 
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detected, including a Rossmann fold-like structure surrounding the key residues 
involved in methyltransferase activity [35, 147]. In addition, the overall 
arrangement of the Core Region and Iceberg Domains are largely intact, and the 
known membrane anchoring domains face outward from the globular body of the 
protein [147]. The differential ability of the Y286, D355, and N376 to affect VEEV 
nsP1 capping activity as well as their locations in highly conserved domains, 
which play integral roles in cap formation, made them strong candidates for 
testing how modulating the capping activity of nsP1 affects SINV infection. 
In order to verify that the SINV nsP1 mutations altered the rate of vRNA 
capping, we assessed what proportion of viral particles contained capped RNA 
genomes. We have shown previously that both capped genomic RNAs and 
ncgRNAs are packaged and released during viral infection [99]. Thus, knowing 
what proportion of capped viral RNA is being packaged into viral particles gives 
insight into the general capping efficiency of nsP1 during viral infection. To this 
end, the comparative assessment of viral capping was accomplished by 
comparing the relative sensitivity of the mutants to RNAse degradation using 
XRN-1, a 5’-3’ exoribonuclease which preferentially degrades RNAs lacking a 
protective 5’ cap structure, in particular 5’ monophosphate RNAs [139, 140]. By 
measuring the amount of RNA resistant to XRN-1 degradation, we were able to 
determine what relative proportion of the total input RNA was capped relative to 
wild type SINV, as the predominant noncapped 5’ end was previously determined 
to be a 5’ monophosphate [99]. As shown in Figure 2.1C, both SINV N376A and 
SINV Y286A had significantly lower proportions of XRN-1 resistant genomic 
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RNAs compared to WT, with SINV Y286A having approximately 25% less XRN-1 
resistant RNA compared to WT, and SINV N376A having approximately 75% 
less XRN-1 resistant RNA. In contrast, and as expected from the previous study 
by Li et al. (2015), SINV D355A was found to have a significantly greater 
proportion of XRN1-resistant RNA, with a mean approximately four-fold greater 
than what was observed for WT SINV. To confirm that the observed resistance of 
the SINV D355A genomic RNAs was due to a cap structure, the genomic RNAs 
were subjected to XRN-1 nuclease treatment in the presence of an established 
decapping enzyme [99, 142, 143]. As shown in Figure 2.1D, enzymatic removal 
of the 5’ cap structure eliminated the resistance of the D355A derived genomic 
RNAs to XRN-1 treatment, resulting in XRN-1 resistances comparable to WT 
SINV. 
From these data, we were able to conclude that the point mutations 
engineered into the SINV nsP1 protein can indeed alter capping activity, both 
negatively, in the case of Y286A and N376A; and positively, as with D355A. 
Therefore, the individual nsP1 mutants can be used to assess the impact of the 
ncgRNAs by modulating the capping activity of nsP1 in tissue culture models of 
infection in a controlled manner.  
 
Increased Capping Decreases SINV Growth Kinetics in Mammalian Cells 
 While the effects of synonymous point mutations on nsP1 capping 
efficiency have been previously characterized for VEEV at an enzymatic level 
[124], the effects of modulating capping activity on viral infection as a whole has 
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not yet been studied in detail. Given the molecular function of the 5’ cap 
structure, one could expect that the SINV nsP1 mutants that decreased vRNA 
capping would show impaired viral growth kinetics relative to wild type virus. 
Likewise, if the ncgRNAs were truly nonfunctional, a mutant that increased 
capping would show enhanced viral growth kinetics in regards to wild type 
infection. As demonstrated by the data presented in Fig. 2.2A, decreasing SINV 
capping modestly decreased viral growth kinetics, as observed for the SINV 
Y286A and SINV N376A mutants. However, the SINV D355A mutant, which 
increased vRNA capping relative to WT, exhibited significantly decreased titers 
over the course of infection (Fig. 2.2A). In addition to a 2-log decrease in viral 
titer, the SINV D355A mutant produced plaques approximately half the size of 
those produced by wild type SINV (Fig. 2.2B and 2.2C). Despite not showing 
significantly decreased viral growth kinetics, both the SINV Y286A and SINV 
N376A mutants also exhibited a small plaque phenotype, albeit not to the same 
extent as the SINV D355A mutant. In addition, all three capping mutants were 
found to have decreased induction of cell death compared to WT SINV (Fig. 
2.2D).  
Collectively, these data indicate that changing the efficiency of vRNA 
capping negatively impacted viral growth kinetics, illustrating that a step in the 
viral life cycle has been detrimentally affected. Furthermore, the viral growth 
kinetics data suggests that SINV is more sensitive to increased vRNA capping 
efficiency than it is to decreased capping efficiency. Thus, the ncgRNAs 
produced during infection are indeed biologically important. Nevertheless, 
55 
 
despite the clear negative impact to viral infection, the precise nature of the 
molecular consequences of increased vRNA capping and decreased presence of 
ncgRNAs cannot be determined from these data alone. As such, the viral gene 
expression and vRNA synthesis profiles of each of the SINV nsP1 mutants were 
next assessed to determine if they were negatively affected by modulation of 
vRNA capping.  
 
Translation of the SINV Genomic RNA Correlates with Capping Efficiency 
 For the majority of mRNAs, a key factor for determining whether or not an 
mRNA is translated is the presence of a functional 5’ cap structure [148-150]. 
Therefore, changing the ncgRNAs to capped genomic RNAs or vice versa by 
altering viral capping efficiency should impact the amount of protein being 
produced by viral RNA during infection. To investigate the effect(s) that 
modulating nsP1 capping efficiency has on viral gene expression, a SINV 
reporter, which contained the open reading frame of nanoluciferase in frame with 
the nsP3 nonstructural protein, was used to measure viral genomic RNA 
translation throughout infection (Fig. 2.3A) [99]. Nanoluciferase expression was 
measured at regular intervals over the course of viral infection (Fig. 2.3B). As 
expected, the SINV D355A mutant, which increased capping relative to wild type, 
exhibited increased genomic vRNA translation compared to WT SINV for every 
time point measured (Fig. 2.3C). Similarly, SINV N376A, which decreased 
capping relative to wild type, showed decreased translation (Fig. 2.3C). 
Curiously, the SINV Y286A mutant showed differential nanoluciferase expression 
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during infection, with translation being slightly increased very early during 
infection, decreased at 8hpi, and similar to wild type at later times post infection.  
 While the SINV nanoluciferase reporter virus allows for the accurate 
quantification of viral gene expression during infection, it does not measure the 
sum accumulation of the nonstructural proteins. To measure the relative 
accumulations of the viral nonstructural proteins, the levels of SINV nsP2 protein 
were assessed via Western blotting at 8, 12 and 16hpi. As shown in Fig. 2.4A 
and quantified in. Fig 2.4B, at 8hpi the accumulation of the SINV nsP2 proteins 
between wild type SINV, SINV D355A, and SINV N376A differed to a statistically 
significant extent. The abundance of nsP2 was increased ~2.5-fold during SINV 
D355A infection, relative to wild type SINV. In contrast, nsP2 levels during SINV 
N376A infections were decreased ~2-fold relative to wild type SINV infections. 
The SINV Y86A mutant was more or less equivalent to wild type nsP2 levels. 
Similar trends were observed at later times during infection. As depicted in Figs. 
2.4C and 2.4D, at 12hpi the SINV nsP2 levels were statistically increased relative 
to wild type infection; however, given the low magnitude of effect, these 
differences are unlikely to be biologically significant. In contrast, at 16hpi SINV 
nsP2 levels were increased to an extent that is likely biologically meaningful (Figs 
2.4E and 2.4F).  
Overall, the levels of genomic translation for the SINV nsP1 mutants nicely 
reflect their relative differences in capping efficiency, with increased vRNA 
capping resulting in increased translation of the nonstructural proteins, and 
decreased vRNA capping resulting in decreased translation at 8hpi. These data 
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are consistent with the conversion of the ncgRNAs to translationally competent 
capped genomic vRNAs. Furthermore, western blotting confirmed the differences 
in translational activity detected during SINV nanoluciferase reporter infections. 
Taken together, the nanoluciferase and western blot data indicate that the 
translation of the genomic vRNAs continues during infection with SINV D355A 
beyond what is observed for wild type SINV. Nonetheless, the biological 
differences in translational activity observed between the SINV D355A mutant 
and its respective parental wild type strain fail to explain the approximately 200-
fold reduction in viral titer. 
 
Modulating SINV Capping Does Not Alter Overall RNA Synthesis or 
Accumulation 
Since differences in viral gene expression failed to outright explain the 
observed decreased viral titers associated with the SINV D355A mutant, we next 
sought to identify if vRNA synthesis was impaired as a result of nsP1 mutation. 
To determine what impact altering viral capping efficiency has on vRNA 
synthesis, the genomic, subgenomic, and minus strand vRNAs were 
quantitatively assessed at 2, 4, and 8 hours post infection via qRT-PCR. At 2hpi, 
the SINV D355A mutant, which has increased vRNA capping relative to wild type 
SINV, produced slightly more SINV genomic and subgenomic RNAs; whereas 
the SINV N376A mutant, which exhibits decreased vRNA capping, produced 
slightly fewer genomic and subgenomic RNAs (Fig. 2.5A). In general, the 
differences in the amount of genomic and subgenomic RNAs being produced by 
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these two capping mutants is reflective of the differences observed in the 
synthesis of their replication machinery (Figs. 2.3 and 2.4). At 4hpi, all three 
SINV nsP1 mutants show a statistically significant deficit in the amount of 
subgenomic RNA present (Fig. 2.5B). Nonetheless, these deficits are unlikely to 
be biologically meaningful due to their overall magnitude of effect relative to wild 
type SINV. By 8hpi however, all three capping mutants show similar levels of all 
three RNA species compared to WT, with the exception of N376A, which had 
less minus strand template compared to WT (Fig. 2.5C).  
Altogether, these data demonstrate that altering the capping activity of 
nsP1 may have impacts on RNA synthesis very early during viral infection, but 
that these differences become muted as infection progresses. Importantly, these 
data indicate that vRNA synthesis on the whole has not been disrupted, 
precluding the possibility that the point mutations made in nsP1 have disrupted 
the function of the other nonstructural proteins. Moreover, similar to that 
described above regarding viral gene expression in the previous section, the ~2-
log reduction in viral growth kinetics observed for the SINV D355A mutant is not 
due to decreased vRNA accumulation or defective vRNA synthesis.  
 
Translation of the SINV Subgenomic RNA is Largely Unaffected by Viral 
Capping 
 Given that neither the differences in nonstructural gene expression or 
vRNA synthesis were capable of explaining the negative impact of the SINV 
nsP1 D355A mutation, we next sought to determine if the function of the 
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subgenomic vRNAs were impacted. As both the genomic and subgenomic 
vRNAs are capped by nsP1, it was hypothesized that mutations which increased 
capping of the genomic vRNAs might impact subgenomic vRNA function. As 
such, it could be expected that these vRNAs would exhibit similar responses to 
altered capping in terms of translation.  In order to determine whether translation 
of the subgenomic vRNAs were impacted similarly to the genomic vRNAs, the 
amount of protein produced late during infection was measured using metabolic 
labeling (Fig. 2.6A). Curiously, both the SINV D355A and SINV N376A mutants 
exhibited a modest decrease in viral capsid production (Fig. 2.6B). In addition, 
none of the SINV nsP1 mutants exhibited differences in regards to the shutoff of 
host translation, a hallmark of alphaviral infection as reviewed in [151], as 
evidenced by the labeling of the cellular Actin protein, relative to WT SINV (Fig. 
2.6C). Interestingly, however, the ongoing synthesis of a high molecular weight 
protein consistent with the nonstructural polyprotein was reproducibly detected 
during the metabolic labeling of SINV D355A mutant infections.  
 Collectively, these data indicate that changes in capping efficiency of the 
genome may either not lead to equivalent changes in capping of the subgenomic 
vRNA; or alternatively, that SINV, and likely other alphaviruses, regulate the 
translation of the structural proteins differently than the nonstructural proteins 
[152]. Regardless, these data suggest that subgenomic translation and host 
translational shutoff are not impacted to a biologically significant degree by 
modulating the efficiency of vRNA capping, and thus are not responsible for the 




Increasing SINV Capping Decreases Viral Particle Production 
Given that the molecular characterizations of the SINV nsP1 mutants had 
so far failed to identify the molecular defect leading to decreased viral growth 
kinetics, we expanded our analyses beyond the lifecycle events most obviously 
affected by the 5’ cap structure. Since vRNA synthesis and viral gene expression 
were unaffected, we next sought to determine whether viral particle assembly 
was negatively impacted by increasing the capping efficiency of the SINV nsP1 
protein. 
To determine whether increasing capping efficiency affected viral particle 
production, we quantified the total number of particles produced by each mutant 
as well as wild type SINV after 24hrs of infection. Similar to what was observed 
during the kinetic analyses of viral infection, increased vRNA capping was 
associated with the production of significantly fewer particles, with the SINV 
D355A mutant producing ~25-fold fewer particles (as measured by genome 
equivalents per ml) than wild type SINV (Fig. 2.7A). In contrast, particle 
production was largely unaffected during infections of the SINV Y286A and SINV 
N376A mutants, which decreased vRNA capping.  
The point mutants utilized in this study are located within, or closely 
adjacent to, the SINV packaging signal [153]. Previous characterizations of the 
alphaviral packaging signals have indicated the importance of stem-loop 
structures which contained a guanosine triplet in the loop region. Mutational 
analyses of the alphaviral packaging elements determined that mutation of the 
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guanosine triplets, or deletion of the packaging element altogether, significantly 
reduced viral titer due to nonselective particle assembly leading to the production 
of alphaviral particles containing the subgenomic vRNAs [153]. Further 
experiments defined that a minimum of two guanosine triplet stem loops was 
sufficient to impart wild type particle production with selectivity for the genomic 
RNA. Even though none of the point mutants used in this study impact either the 
guanosine triplets, or the general secondary structures (as predicted by in silico 
analysis), the potential for the inhibition of assembly by a non-capping 
mechanism existed, warranting further assessment of particle production during 
SINV nsP1 mutant infections. As mentioned earlier, disruption of the alphaviral 
packaging signal leads to the production of viral particles containing 
predominantly subgenomic RNAs [153]. As shown in Fig. 2.7B, quantitative 
determinations to identify which specific vRNAs were packaged into wild type 
and SINV nsP1 mutant viral particles indicated no aberrant packaging of the 
SINV subgenomic RNA, consistent with an intact functional packaging signal.  
The high degree of similarity between the relative magnitude of effect 
regarding decreased viral titer and viral particle production during SINV D355A 
infection indicates that particle assembly, and not the slight perturbations in 
vRNA synthesis or structural gene expression, is primarily responsible for 
decreased viral growth kinetics. Importantly, these data suggest that SINV, on 
the whole, is much more tolerant of mutations which decrease capping efficiency 
than those that increase capping efficiency, and that by increasing the capped to 
noncapped viral RNA ratio, viral particle production has been detrimentally 
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affected. Moreover, these data validate that the packaging signal remains 
functional in the presence of the nsP1 point mutations described in this study.  
 
Discussion  
The capping of SINV genomic vRNAs can be modulated by point mutations 
in nsP1 
 The data shown in Fig. 2.1 indicates that, in SINV, 5’ capping of the 
genomic vRNA can be modulated via single point mutations in the nsP1 protein. 
This is true for both increasing vRNA capping, as seen with SINV D355A, and 
decreasing capping, as seen with SINV Y286A and SINV N376A. Moreover, 
vRNA capping can also be modulated to different extents, as seen with SINV 
Y286A and SINV N376A, which decreased vRNA capping by 25% and 75%, 
respectively. The ability to change nsP1 capping efficiency in a controllable 
manner opened up new avenues to explore the molecular and biological 
importance of both the capped genomic vRNAs and the ncgRNAs during 
infection in tissue culture models of infection and in vivo.  
From the data above, we may conclude that a primary consequence of 
mutating the SINV nsP1 protein is the alteration of vRNA capping. Nonetheless, 
the alphaviral nonstructural proteins interact with one another during infection 
[154-157]. Previous studies have shown that disrupting these interactions by 
mutation results in poorer viral infection and, more specifically, leads to severe 
defects in vRNA synthesis [154-156]. However, the disruption of nonstructural 
protein interactions is unlikely with the nsP1 mutants reported in this study, as 
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the phenotypes described for situations where the interactions between the 
nonstructural proteins have been disrupted are inconsistent with what is reported 
here. For example, several residues in nsP4 have been reported as important for 
interactions with nsP1, such as G38L in nsP4 [154]. When this residue in nsP4 
was mutated, viral infection exhibited decreased growth kinetics and a small 
plaque phenotype. However, a hallmark of disrupting the nonstructural protein 
interactions was the severely decreased synthesis of minus strand vRNA 
throughout the course of infection [154, 156]. As seen in Fig. 2.5, none of the 
nsP1 mutants examined in this study exhibited a significant deficit in production 
of any viral RNA species, with the exception of a minor decrease in minus strand 
vRNA synthesis by N376A. It is of note that the nsP4 G38L mutant was able to 
be rescued by an additional mutation in nsP1 at N374 [154]. The nsP1 N374 
mutation resulted in complete restoration of viral titer and partial restoration of 
minus strand vRNA synthesis in the nsP4 G83L background compared to wild 
type. While the effect of mutating nsP1 N374 on capping efficiency is not known, 
one could speculate that, given its proximity to other residues which we have 
shown alter capping activity, that modulating the capping efficiency of nsP1 could 
be a way of coping with the detrimental nsP4 G38L mutation, which creates a 
severe defect in RNA synthesis.  In addition to this, a previous study has 
reported that the region in nsP1 encompassing the SINV point mutations utilized 
here possess little to no interaction with the nsP2 protein [157]. Thus, for the 
reasons described above, the nsP1 residues mutated during this study are likely 
not involved in mediating nonstructural protein interactions, and the resulting 
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deficits in the viral lifecycle are not due to disrupted nonstructural protein 
interactions. 
 
SINV infection is more sensitive to increased capping than decreased 
capping 
 Multiple studies have shown that polymorphisms in nsP1 have profound 
effects on virulence. Mutations in regions of nsP1 have been shown to alter 
vRNA synthesis, viral titer, viral sensitivity to IFN, and disease severity in vivo 
[97, 154, 158]. Certain residues, such as nsP1 H39 in SINV, completely abrogate 
viral infection by eliminating the methyltransferase activity of the nsP1 protein 
[35, 134, 159]. Therefore, we expected that incorporating the point mutations 
which alter viral capping would have impacts on viral infection. However, we 
were surprised to find that while the increasing capping mutant was found to 
have decreased viral growth kinetics, the decreased capping mutants were not 
significantly different from wild type SINV (Fig. 2.2A). This result was especially 
surprising when it was found that all three capping mutants had small plaque 
phenotypes and decreased cell death, yet D355A was the only mutant to show 
altered growth kinetics (Fig. 2.2B, C, and D). Serial passaging of the mutants 
used in this study have indicated that they are stable for at least 4 sub-passages, 
as no reversion events (based on plaque phenotype) were observed for any of 
the SINV nsP1 mutants. This suggests that SINV is more detrimentally impacted 
by changes which increase the amount of capped vRNA present than those 
which decrease capping efficiency. Thus, increasing the capping efficiency of the 
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SINV nsP1 protein, which effectively reduced the production of the ncgRNAs, 
indicates that the ncgRNAs are biologically important to viral infection.  
 
Altering capping leads to changes in genomic translation but not RNA 
synthesis or subgenomic translation 
As would be expected, changes in nsP1 capping efficiency correlated with 
changes in genomic vRNA translation. In addition, the reduced presence of the 
ncgRNAs correlated with increased translation of the viral genomic RNA 
throughout infection, as can be seen with the increased capping mutant SINV 
D355A. Furthermore, decreasing the capping efficiency of the nsP1 protein, as 
evidenced by the SINV N376A mutant, modestly decreased translation. 
Admittedly, the second decreased capping mutant, SINV Y286A, did not follow 
the same pattern as the SINV N376A mutant. This may be due to the 
comparatively minor decrease in capping efficiency caused by SINV Y286A not 
being significant enough to consistently alter the vRNA population leading to 
dysregulated genomic translation.  
However, the increased translation exhibited by the SINV D355A mutant 
did not lead to lasting compounding biological effects, at least in tissue culture 
models of infection. For instance, despite there being more replication machinery 
being produced early during SINV D355A infection, there were no overt 
differences in the synthesis of any of the viral RNA species during the time points 
tested (Fig. 2.5). This suggests that increasing or decreasing the production of 
the nonstructural proteins alone is not enough to alter RNA synthesis over the 
66 
 
long term in highly permissive tissue culture models of infection. Nonetheless, 
due to technical limitations we were unable to accurately assess vRNA synthesis 
earlier than two hours post infection. Hence, the possibility that vRNA synthesis 
is enhanced very early during infection remains unaddressed.  
 Another unexpected result was that changes in capping efficiency seems 
to affect subgenomic translation differently than genomic translation. The data 
presented in Fig. 2.6 show that both the increased and decreased capping 
mutants SINV D355A and SINV N376A demonstrate slight, biologically 
unmeaningful, decreases in capsid production at 16hpi, despite having notable 
differences in nonstructural gene expression (Figs. 2.3 and 2.4). This suggests 
that either capping efficiency is regulated differently for the subgenomic RNA 
than for the genomic RNA, resulting in no differences in capping efficiency for the 
subgenomic RNA, or that translation of the subgenomic RNA is less dependent 
on the presence of a 5’ cap than the genomic RNA during infection.  The latter is 
supported by previous studies which demonstrate that the eIF4F complex, which 
includes the cap-binding eIF4E, is not needed in order to initiate translation of the 
alphaviral subgenomic RNA [152, 160]. These previous studies, along with the 
data presented here, suggests that translation of the subgenomic RNA is 
unaffected, at least in part, by modulation of vRNA capping. 
 In addition to there being little effect on subgenomic translation, there was 
also shown to be no differences in terms of host translational shutoff between 
any of the capping mutants and WT SINV (Fig. 2.6C). This further supports that 
the point mutations made in nsP1 are not negatively affecting interactions 
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between nonstructural proteins, because disruptions between nsP1 and nsP4 
have been previously found to negatively affect host translational shutoff [154]. 
Host translational shutoff, for SINV at least, has been largely attributed to the 
translation of the structural proteins [161]. Therefore, it is unsurprising that there 
is no change in host shutoff between the capping mutants and the WT SINV 
given that there is little difference in subgenomic expression. 
 
Decreased titer due to changes in capping caused by interference with 
particle production 
 The decreased viral growth kinetics observed during SINV D355A 
infection correlated remarkably with decreased particle production. However, the 
congruence of the decrease in infectious units and viral particles infers that viral 
infectivity is, more or less, identical for all of the viral strains. The discrepancy 
between the two magnitudes of effect (an approximate 5-fold difference) are 
likely due to confounding variations in the accuracy and precision of the two 
measurements. Nonetheless, it remains possible that the viral particles have 
differences in their basal infectivity. Studies examining earlier effects of the 
ncgRNAs are ongoing and will be presented in a follow up study.  
 The observation that decreased particle production is the primary 
molecular defect during SINV D355A infections suggests that increasing the 
amount of capped genomic RNAs, thereby decreasing the number of ncgRNAs, 
negatively impacts the assembly of nascent viral particles. Whether or not the 
increased capping activity is directly, or indirectly, responsible for the packaging 
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phenotype isn’t definitively known. Characterizations of SINV packaging indicates 
selectivity remains intact during the SINV D355A assembly process despite 
decreased particle production overall, as the packaging of subgenomic vRNAs 
was not observed. This is indicative of a functional alphaviral packaging signal 
despite the incorporation of minor point mutants into the region defined as the 
packaging signal for SINV. Moreover, the SINV Y286A mutant which also resides 
within the SINV packaging element lacks an appreciable packaging phenotype. 
Thus, the assembly phenomena associated with the SINV D355A mutant cannot 
be simply explained by disruption of the alphaviral packaging signal.  
While the underlying mechanism is unclear, the data presented above 
indicates that nonstructural protein expression is increased relative to wild type 
parental virus, and remains increased well into the late stages of infection during 
SINV D355A infections. Collectively, these data indicate that decreasing the 
production of the ncgRNAs perturbs viral genomic RNA function beyond the 
individual RNA level, as apparent compounding effects on the genomic RNA 
population are observed. Precisely how the translationally inactive ncgRNAs 
serve to modulate genomic vRNA function as a whole, leading to efficient particle 
assembly, is unknown.  
We propose that, as diagrammed in Fig. 2.8, during wild type infections, 
the translationally inactive, ncgRNAs temper the molecular activities of the 
translationally active, capped genomic vRNA population allowing for the temporal 
progression of infection to lead to the assembly and release of viral particles. We 
postulate that the ncgRNAs, due to their lack of translational capacity, interact 
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with a unique set of host factors relative to the capped translationally competent 
genomic RNAs. Collectively, these interactions lead to the development of a pro-
assembly microenvironment by excluding host factors that either inhibit the 
assembly process, or promote nucleocapsid disassembly. For instance, if the 
ncgRNAs foster an non-translational environment through the interaction of host 
factors, such as those found within stress granules, the 60S ribosomal subunit, 
which is implicated in nucleocapsid disassembly would be excluded from the 
local microenvironment, allowing assembly to occur unimpeded [26, 162]. 
However, when the genomic RNA population is altered by increasing the 
efficiency of genomic RNA capping, such as observed with the SINV D355A 
mutant, the increased and continuous translational activity of the genomic vRNA 
culminates in the formation of a pro-translational vRNA “pool” that is refractory to 
encapsidation and particle assembly. Work examining such possibilities are 
ongoing in the Sokoloski lab and will be reported in the future.  
 
Conclusions 
 Collectively these data affirm the existence and biological importance of 
the ncgRNAs during SINV infection. This assertion is directly supported by the 
capacity to modulate the capping activities of nsP1 protein via site directed 
mutagenesis resulting in the increased production of XRN-1 resistant genomic 
vRNAs without increased overall genomic RNA numbers. Moreover, the 
preponderance of gene expression data indicating increased translation brought 
about by increasing the capping of the genomic vRNA supports the existence of 
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the alphaviral ncgRNAs at a functional level. Finally, the molecular 
characterizations of SINV nsP1 mutant infections provides insight into the 
biological importance of the ncgRNAs in regards to the regulation of alphaviral 




Figure 2.1. Point mutations in the nsP1 protein of SINV alter 5’ vRNA 
capping efficiency. (A) Amino acid sequence alignment of selected alphavirus 
nsP1 proteins. The individual nsP1 protein sequences of Sindbis (ViPR-U38305), 
Venezuelan Equine Encephalitis (VEEV, ViPR-L01443), Chikungunya virus 
(CHIKV, ViPR-DQ443544), and Ross River virus (RRV, ViPR-GQ433359) were 
aligned by Clustal Omega. (B) An ITASSER predicted structure of the SINV nsP1 
protein. Amino acid residues of importance are highlighted as follows- 
Red=Y286, Green=D355, Blue=N376, Cyan=amphipathic helix, and the residues 
involved in the methyltransferase activities, including H39 which binds to the 
m7GMP residue are pink. (C) A graph depicting the relative quantity of XRN-1 
resistant vRNA isolated from viral particles produced by BKH-21 cells infected 
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with wild-type SINV or the individual capping mutants 24hpi. (D) Identical to 
panel C, with the exception that the viral genomic RNAs were enzymatically 
decapped concurrent with XRN-1 treatment. All quantitative data shown 
represents the means of a minimum of three independent biological replicates 
utilizing 3 independent particle preparations, with the error bars indicating the 
standard deviation of the means. P-Values, as indicated on the figure, were 






Figure 2.2. Altering viral capping efficiency negatively impacts viral 
infection. (A) One-step growth kinetics of the individual capping mutants and 
parental wild type SINV as observed in BHK-21 cells infected at an MOI of 0.5 
PFU/cell. Statistical significance was determined by area under the curve 
analysis. (B) Plaque morphology of wild type SINV and capping mutant viruses in 
BHK-21 cells overlaid with 1 0.5% solution of Avicel at 24h post-infection. (C) A 
graph indicating the average plaque diameter of the mutant viruses relative to 
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wild type SINV. Size was determined by ImageJ software (NIH). (D) Cell viability 
of BHK-21 cells infected with the individual capping mutants at 24hpi relative to 
mock infected BHK-21 cells. All quantitative data shown represent the means of 
at least three independent biological replicates, with the error bars representing 
standard deviations of the mean. Statistical significance, as indicated within each 





Figure 2.3. Translation of the genomic vRNA correlates with viral capping 
efficiency. (A) Schematic diagram of the SINV nanoluciferase reporter used in 
this study. (B) BHK-21 cells were infected with either parental wild type, or an 
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individual SINV capping mutant nanoluciferase reporter strain. The level of 
nanoluciferase activity was quantified at the indicated times post infection. C) 
The nanoluciferase activity, as reported in panel B, normalized to wild type 
expression at each individual time point to enable readers to identify differences 
in translation. All the quantitative data shown represent the means of three 
independent biological replicates, with the error bars representing standard 
deviations of the mean. Statistical significances, as indicated in the figure, were 
first determined using ANOVA analyses followed by post-hoc statistical analyses 





Figure 2.4. nsP2 protein levels are impacted by mutation of the nsP1 
protein. (A) BKH-21 cells were infected with wild type SINV or an individual 
capping mutant at an MOI of 5 PFU/cell and assessed by western blotting to 
determine the abundance of nsP2 at 8hpi. Actin is shown as a loading control. B) 
Densitometric quantification of the nsP2 protein normalized to Actin levels at 
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8hpi. Panels C and D) Western blots and densitometry analyses identical to 
those described for panels A and B, with the exception that the timing of the 
assay coincided to 12hpi. Panels E and F) Western blots and densitometry 
analyses identical to those described for panels A and B, with the exception that 
the timing of the assay coincided to 16hpi. The Western blot images shown are 
representative of at least three independent biological replicates. All the 
quantitative data shown represent the means of three independent biological 
replicates, with the error bars representing standard deviations of the mean. 
Statistical significances, as indicated in the figure, were first determined using 







Figure 2.5. Altering vRNA capping efficiency impacts early RNA synthesis. 
(A) BHK-21 cells were infected with either wild type parental SINV or an 
individual capping mutant virus at an MOI of 5 PFU/cell. At 2 hours post infection, 
the total cellular RNA was extracted and assessed for the absolute quantities of 
the genomic, subgenomic, and minus-strand vRNAs by qRT-PCR. (B and C) 
Identical to panel A with the exceptions that the time points are 4 and 8 hours 
post infection, respectively. All the quantitative data shown represent the means 
of three independent biological replicates with the error bars representing 
standard deviations of the mean. Statistical significances, as indicated in the 
figure, were first determined using ANOVA analyses followed by post-hoc 
statistical analyses by Student’s t test. P-Values as determined by Student’s t 
test are represented by *, p<0.05. **, p<0.01. ***, p<0.001. #, one of the 






Figure 2.6. Subgenomic gene expression is unaffected by altering SINV 
vRNA capping. (A) BHK-21 cells were either mock treated or infected with wild 
type SINV or an individual capping mutant at an MOI of 10 PFU/cell. At 14hpi, 
the cells were pulsed with L-AHA for a period of 2 hours. Afterwards, the cells 
were harvested and equal cell volumes of cell lysate were analyzed by SDS-
PAGE and fluorescent imaging. The data shown are representative of three 
independent biological replicates. (B) Densitometric quantification of the SINV 
capsid protein, with intensity relative to wild-type SINV shown. (C) Densitometric 
quantification of the host actin protein with intensity relative to wild type SINV. All 
the quantitative data shown represents the means of three independent 
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biological replicates with the error bars representing standard deviations of the 






Figure 2.7. Analysis of SINV particle production. A) BHK-21 cells were 
infected with either wild-type SINV or an individual capping mutant at an MOI of 5 
PFU/cell. At 24hpi the total number of viral particles produced was measured 
using qRT-PCR. Data shown represents the means of at least 6 independent 
biological samples. B) Quantitative determination of the composition of the 
encapsidated viral RNAs in mature extracellular viral particles. Samples of virus 
containing supernatants were assessed to determine the absolute quantities of 
the genomic and subgenomic RNAs via standard curve qRT-PCR.  All the 
quantitative data shown represent the means of three independent biological 
replicates, with the error bars representing standard deviations of the mean. 
Statistical significances, as indicated in the figure, were first determined using 





Figure 2.8. Proposed model of how increasing genomic vRNA capping 
negatively impacts viral infection. Wild-type SINV infection produces a low 
capped population of vRNAs that are weakly pro-translational and enables 
efficient particle production (top). Conversely, the increased capping nsP1 
mutant D355A produces a population of vRNAs that are largely capped and 
therefore strongly pro-translational, which subsequently leads to impaired particle 







PRODUCTION OF NONCAPPED GENOMIC RNAS IS CRITICAL TO SINDBIS 
VIRUS DISEASE AND PATHOGENICITY2 
 
Summary 
Alphaviruses are positive-sense RNA viruses that utilize a 5’ cap structure 
to facilitate translation of viral proteins and to protect the viral RNA genome. 
Nonetheless, significant quantities of viral genomic RNAs that lack a canonical 5’ 
cap structure are produced during alphaviral replication and packaged into viral 
particles. However, the role/impact of the noncapped genomic RNA (ncgRNA) 
during alphaviral infection in vivo has yet to be characterized. To determine the 
importance of the ncgRNA in vivo, the previously described D355A and N376A 
nsP1 mutations, which increase or decrease nsP1 capping activity respectively, 
were incorporated into the neurovirulent AR86 strain of Sindbis virus to enable 
characterization of the impact of altered capping efficiency in a murine model of 
infection. Mice infected with the N376A nsP1 mutant exhibited slightly decreased 
rates of mortality and delayed weight loss and neurological symptoms, although 
levels of inflammation in the brain were similar to wild type infection. Although the 
 
2 This chapter is adapted from work published in mBio, 2020, Volume 11, Issue 6 with the same 
title under a Creative Commons Attribution (CC BY) license 163. LaPointe, A.T., et al., Production 





D355A mutation resulted in decreased antiviral gene expression and increased 
resistance to IFN in vitro, mice infected with the D355A mutant showed significantly 
reduced mortality and morbidity compared to mice infected with wild type virus. 
Interestingly, expression of proinflammatory cytokines was found to be significantly 
decreased in mice infected with the D355A mutant, suggesting that capping 
efficiency and the production of ncgRNA are vital to eliciting pathogenic levels of 
inflammation. Collectively, these data indicate that the ncgRNA have important 
roles during alphaviral infection and suggest a novel mechanism by which 
noncapped viral RNA aid in viral pathogenesis. 
 
Introduction 
 Alphaviruses are positive-sense, single-stranded RNA arboviruses that 
are capable of causing severe disease. The natural enzootic transmission cycle 
of these viruses is between a mosquito vector and a mammalian host, typically 
rodents or birds, although epizootic spillover events can occur that result in 
infection of humans and equids. Alphaviruses are broadly categorized as either 
arthritogenic or encephalitic based on disease symptomology. The arthritogenic 
alphaviruses, such as Chikungunya virus (CHIKV) and Ross River Virus (RRV) 
are capable of causing disease ranging from mild febrile illness to severe 
polyarthralgia, which can persist anywhere from weeks to years following 
infection [4, 11, 164]. In contrast, the encephalitic alphaviruses, such as 
Venezuelan Equine Encephalitis virus (VEEV) and some strains of Sindbis virus 
(SINV), like the AR86 strain used in this study, can cause mild to severe 
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neurological symptoms, including encephalitis that can potentially lead to the 
death of the host [11, 12, 165]. While alphaviruses pose a large threat to public 
health, there are currently no safe and effective vaccines or antiviral therapies to 
prevent or treat alphaviral disease. 
 Alphaviruses produce three RNA species during infection: the genomic 
strand, which encodes the nonstructural proteins; the minus-strand RNA 
template; and the subgenomic RNA, which encodes the structural proteins. Both 
the genomic and subgenomic RNAs have a type 0 cap structure added to their 5’ 
ends to facilitate translation and protect the 5’ end of the transcripts [129-131]. 
The addition of the cap structure to the 5’ end of viral RNAs is primarily carried 
out by nonstructural proteins 1 and 2 (nsP1, nsP2). NsP2 removes the 5’ γ-
phosphate from the nascent vRNA molecule while, in a separate reaction, the 
methyltransferase domain of nsP1 catalyzes the addition of a methyl group from 
S-adenosylmethionine to a GTP molecule, forming a covalent m7GMP-nsP1 
intermediate [40, 132]. The m7GMP moiety is then transferred to the 5’end of the 
vRNA molecule by the guanylyltransferase activities of nsP1, resulting in the 
7meGppA type 0 cap structure [133].  
In response to the lack of preventatives or treatments, targeting the 
alphaviral replication machinery has been a popular approach for developing 
potential antiviral therapies. Capping of the genomic and subgenomic vRNA is 
vital for successful viral replication, as mutations which completely inhibit capping 
of the viral RNA render the virus noninfectious. Thus, because nsP1 is 
responsible for the alphaviral capping process, it has been a popular target for 
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antiviral research. In particular, a number of compounds have been developed 
which inhibit nsP1 capping activity and reduce viral replication in vitro, but, to 
date, none have been tested for efficacy against alphaviral infection in vivo [166-
169]. In addition to the development of drugs against nsP1 activity, multiple 
residues in nsP1 have also been identified as determinants for alphaviral 
virulence, however the impact of these residues on alphaviral capping efficiency 
has never been delineated. The SINV nsP1/nsP2 cleavage mutant T538I has 
been shown to determine pathogenicity in mouse models of infection by altering 
nonstructural polyprotein processing and the virus’ sensitivity to interferon [101, 
170].  More recently, a group of six mutations in the nsP1 of RRV have also been 
shown to attenuate alphaviral disease in mice, although the mechanism of 
attenuation and the impacts of these mutations on alphaviral replication have yet 
to be fully characterized [97, 98]. These studies illustrate the significance of nsP1 
to alphaviral infection and pathogenicity, but have yet to determine the 
importance of alphaviral capping efficiency and the production of the ncgRNAs to 
in vivo infection. 
 While capping of the viral RNA is critical to viral protein expression and 
viral replication, we have previously shown that the genomic vRNA are not 
universally capped, and that a significant proportion of the alphaviral genomic 
RNA produced and packaged during infection lack the 5’ cap structure [99]. In 
addition, our recently published study showed that the proportion of noncapped 
genomic RNA (ncgRNA) produced during SINV infection could be altered using 
point mutations in nsP1 to modulate capping activity [171]. Specifically, 
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incorporating a D355A mutation in the nsP1 of SINV resulted in increased 
capping efficiency, and therefore decreased ncgRNA production, relative to wild 
type SINV. Alternatively, a N376A mutation in nsP1 resulted in decreased 
capping efficiency and increased ncgRNA production. By utilizing these 
mutations to alter ncgRNA production, we were able to show that increasing the 
capping efficiency of nsP1 was detrimental to SINV infection in tissue culture 
models of infection, while decreasing nsP1 capping efficiency did not significantly 
affect viral titer or overall replication.  
However, the presence or lack of a phenotype in vitro is not always 
indicative of what will occur during infection in vivo. As such, the goal of this 
study was to determine the effect of altered ncgRNA production on alphaviral 
pathogenesis by using the previously described nsP1 capping mutants in a 
mouse model of infection. The data presented here show that modulating 
ncgRNA production through the use of the D355A and N376A point mutations to 
alter nsP1 capping efficiency in nsP1, has a profound impact on alphaviral 
pathogenesis. In specific, decreasing capping efficiency resulted in increased 
sensitivity to type-I IFN and a slight decrease in mortality. Surprisingly, increasing 
capping efficiency resulted in almost complete abrogation of morbidity and 
mortality, despite showing increased resistance to type-I IFN, due to reduced 
immune infiltration and production of inflammatory cytokines in the brain. 
Collectively, our findings indicate that the ncgRNA are important in determining 
the host immune response to viral infection and play a critical novel role in 




Materials and Methods 
Tissue culture cells. Baby Hamster Kidney 21 (BHK-21) fibroblast cells (a gift 
from Dr. R. W. Hardy, Indiana University – Bloomington) and interferon 
competent L929 mouse fibroblast cells (a gift from Dr. P. Danthi, Indiana 
University - Bloomington) were maintained in minimal essential media (MEM; 
Cellgro) containing fetal bovine serum (FBS; Atlanta Biologicals), 1% Penicillin-
Streptomycin (Cellgro), 1% nonessential amino acids (Cellgro), and 1% L-
glutamine (Cellgro). SK-N-BE(2) human nerve cells (a gift from Dr. L. Beverly, 
University of Louisville) were maintained in Dulbecco's Modified Eagle Medium 
(DMEM)/F12 media containing 10% FBS, 1% Penicillin-Streptomycin, and 1% L-
glutamine. All cell lines were cultured at 37o C and 5% CO2 in a humidified 
incubator. Regular passaging using standard subculturing techniques was used 
to maintain low passage stocks. 
 
Generation of AR86 SINV capping mutants. The AR86 SINV nsP1 mutants 
used in this study were generated by Gibson Assembly via the use of a Gibson 
Assembly HiFi 1-step kit (SGI), using a restriction-digested AR86 cDNA plasmid 
and a synthetic DNA fragment, according to manufacturer’s instructions [165]. 
Mutants were verified by whole-genome sequencing; full-genome sequences are 




Production of wild-type and mutant SINV Stocks. Wild-type, D355A, and 
N376A SINV AR86 were prepared by electroporation, as previously described 
[137]. Approximately 2.8x106 BHK-21 cells were electroporated with 10μg of in 
vitro-transcribed RNA. This was done using a single pulse at 1.5kV, 12mA, and 
200 Ω from a Gene Pulse Xcell system (BioRad) as previously described [171]. 
Afterwards, cells were incubated under normal conditions until cytopathic effect 
was apparent, at which point the supernatant was collected, clarified via 
centrifugation at 10,000xg for 10min at 4oC, and aliquoted into small volume 
stocks which were stored at -80oC for later use. 
 
Capping Assay. To define the impact of the nsP1 mutations on the capping 
activity of the alphaviral replicase complex, a linker-ligation mediated approach 
was used. Briefly, BHK-21 cells were infected with the aforementioned SINV 
AR86 nsP1 mutants at an Multiplicity of Infection (MOI) of 5 Infectious Units (IU) 
per cell, and at 16 hours post infection (hpi) total RNA was extracted from the 
cells via TRIzol. As our previous studies have indicated that the 5’ end of the 
noncapped viral transcripts are poly-phosphorylated, the total RNA samples must 
be initially dephosphorylated prior to completing the linker-ligation method (which 
requires a 5’ monophosphate) [99]. To this end, 1ug of RNA was 
dephosphorylated via treatment with Antarctic Phosphatase (NEB, M0289S) as 
per the manufacturer’s instructions. After a 30 minute incubation period at 37⁰C, 
the Antarctic Phosphatase was heat inactivated by incubating the reaction 
mixture for 2 minutes at 80⁰C prior to rapid cooling on ice. The dephosphorylated 
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RNAs were then equally divided into two reactions to further prepare the 
noncapped and capped transcripts for linker-ligation and qRT-PCR analysis. To 
enable the detection of the noncapped viral RNAs, the dephosphorylated RNAs 
were treated with T4 Polynucleotide Kinase (PNK; NEB, M0201L) as per the 
manufacturer’s instructions. In parallel, the capped RNAs were further prepared 
for linker-ligation via incubation in the presence of RNA 5’ Pyrophosphohydrolase 
(RppH; NEB, M0356S), as per the manufacturer’s instructions. Both the T4 PNK 
and RppH reactions were incubated for a period of 30 minutes at 37ºC prior to 
phenol chloroform extraction and ethanol precipitation. The RNA pellets were 
resuspended in 20ul of nuclease-free water and used as the input materials for 
the linker-ligation reaction described below to enable the detection of the 
noncapped and capped vRNAs via qRT-PCR.  
 The prepared RNAs were then ligated to an RNA linker that was blocked 
on the 5’ end with a 9 carbon spacer (RNA Linker- 5’-5Sp9-
GUUCAGAGUUCUACAGUCCGACCCAUC-3’) via T4 RNA Ligase 1. Briefly, 
each 30ul reaction mixture consisted of 0.5ugs of prepared RNA (as described 
above), 1X T4 RNA Ligase Buffer, 1mM ATP (final concentration), 1.66uM RNA 
Linker Oligo (final concentration), 10 Units (U) of T4 RNA Ligase 1 (NEB, 
M0204S), and 40U of RNAse Inhibitor (NEB, M0314S). The linker-ligation 
reactions were incubated at 25⁰C for a period of 2 hours prior to phenol 
chloroform extraction and ethanol precipitation. The linker-ligated RNAs were 
resuspended in 20ul of nuclease-free water, and 5ul of the ligated RNAs were 
used as the input for Reverse Transcription (RT) reactions using OneScript Plus 
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RT (Abmgood, G237) as per the manufacturer’s instructions. To enable the 
specific amplification of the viral genomic RNA, the RT reactions were primed 
with SINV.nSP1.R oligo (5’-AACATGAACTGGGTGGTGTCGAAG-3’). The 
composition of the SINV genomic RNA 5’ ends were then quantitatively assessed 
via qRT-PCR as previously described using primer sets specific for the RNA 
linker as well as for nsP1 [99]. The amount of linker-containing genomic RNAs 
relative to the total genomic RNA level was then calculated using the ΔΔCT  
method in order to determine the ratio of capped or noncapped RNA present, 
depending on the sample treatment described above. The primers used for this 
experiment are listed in Supplemental Table 1.  
 
Analysis of viral growth kinetics. To determine if the mutation of the SINV 
nsP1 protein  negatively impacted AR86 SINV infection, one-step viral growth 
kinetics for each capping mutant were assayed in tissue culture models of 
infection. BHK-21 cells were seeded in a 12-well plate and incubated under 
normal conditions until cell monolayers were 80-90% confluent. The cells were 
then infected with either wild-type virus or the individual capping mutant virus at 
an MOI of 5 IU/cell and the virus was allowed to adsorb for 1 h. The inoculum 
was then removed, the cells were washed with 1x phosphate buffered saline 
(PBS) to remove any unbound viral particles, and whole medium supplemented 
with 25mM HEPES was added. The cells were incubated at 37o C and tissue 
culture supernatants were harvested (and the media replaced) at the indicated 




Quantification of infectious virus by plaque assay. In order to determine 
infectious viral titer of all viral samples produced during this study, standard 
virological plaque assays were used. To summarize, BHK-21 cells were seeded 
in 24-well plates under normal incubation conditions until the cell monolayers 
were 80-90% confluent. At that point, the cells were inoculated with 10-fold serial 
dilutions of virus containing samples followed by a 1-hour adsorption period. 
Afterwards, cells were overlaid with a solution of 0.5% Avicel (FMC Corporation) 
in 1x media for 48 h [138]. The monolayers were then fixed with formaldehyde 
solution (3.8% formaldehyde-1x PBS) for at least 1 h. The overlay was then 
removed, and the plaques were visualized via crystal violet staining. 
 
Western Blot. To determine whether or not altering the capping efficiency 
impacted the expression of the SINV nonstructural genes, the expression of 
nsP2 was assessed via Western blotting. Briefly, whole-cell lysates were 
generated from BHK-21 cells that were infected with either wild type SINV AR86, 
one of the aforedescribed nsP1 mutants, or Mock infected. At 8 hours post 
infection, the cells were lysed via the addition of RIPA buffer (50mM Tris-HCL 
(pH 7.5) – 50mM NaCl – 1% (v/v) Nonidet P40 (NP-40) – 0.5% (w/v) SDS – 
0.05% (w/v) sodium deoxycholate – 1mM EDTA) followed by vigorous vortexing 
prior to storage at -80⁰C until further use. Equal amounts of whole-cell lysates 
were resolved using SDS-PAGE and transferred to nitrocellulose membranes for 
downstream immunodetection. The resulting blots were probed for anti-SINV 
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nsP2 polyclonal sera (a gift from R.W. Hardy at Indiana University-Bloomington) 
and anti-Actin (ThermoFisher, clone mAGGEa), and probed with the appropriate 
HRP-labeled secondary antibodies using the iBind Flex Western System with 
HRP detection / blotting reagents (ThermoFisher). Detection of the SINV nsP2 
and host Actin proteins was accomplished via chemiluminescence with 
SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher, 
34579) detected by an Azure C200 Imaging Station (Azure Biosystems, C200). 
 
RNA Kinetics. BHK-21 cells were infected with either wild type SINV AR86, or 
one of the aforementioned SINV nsP1 mutants at an MOI of 5 IU/cell. At the 
indicated times post-infection, the total RNA was isolated from the infected cells 
via TRIzol reagent, as according to the manufacturer’s instructions. Paired RT 
reactions were assembled using 1ug of total cellular RNA and primer sets 
designed to prime the synthesis of cDNA from the viral RNA species in a 
transcript specific manner. Briefly, the positive-sense RNAs were primed for 
cDNA synthesis using SINV.nsP1.R (5’-AACATGAACTGGGTGGTGTCGAAG-3’) 
and SINV.E1.R (5’-ATTGACCTTCGCGGTCGGATACAT-3’), and the negative 
sense RNAs were primed for cDNA synthesis using SINV.nsP1.F (5’-
AAGGATCTCCGGACCGTA-3’). All RT reactions also included an oligo priming 
for the mammalian 18S rRNA, Mam.18S.R (5’-AGTCGGCATCGTTTATGGTC-
3’). qRT-PCR detection of the viral RNA species was accomplished using a 
standard curve analysis and subtractive method as previously described [171]. 
To determine the amount of subgenomic vRNA present, the absolute quantities 
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of RNA detected with the nsP1 primer set were subtracted from that detected 
with the E1 primer set, as the E1 primer set will detect both the genomic and 
subgenomic RNAs, but the nsP1 primer set will only detect the genomic RNA. 
Primer pairs are listed in Supplemental Table 1. 
 
Type-I IFN sensitivity assay. L929 cells were seeded in a 48 well plate and, 
upon reaching 80-90% confluency, were inoculated with either wild-type parental 
virus or one of the individual capping mutants at an MOI of 10 IU/cell. After a 1 h 
adsorption period, the inoculum was removed, the cells were washed twice with 
1x PBS, and whole media was added. At the indicated times post infection, 20 
international units (IU) of murine type-I IFN (R&D Systems) was added to the 
media. Supernatants were collected at 24hpi and viral titer was determined by 
plaque assay. To calculate the relative sensitivity, the difference in viral titer 
between the type-I IFN treated and untreated infections was calculated at each 
time point for each virus. These differences were then calculated relative to the 
differences seen during wild-type SINV infection in order to determine relative 
sensitivity to type-I IFN.  
 
Detection of ISG and IFNβ transcripts. To determine abundance of IFNβ and 
the listed ISG transcripts, L929 cells were seeded in a 24-well plate and, upon 
reaching 80-90% confluency, were inoculated with wild-type SINV or one of the 
capping mutants at an MOI of 10 IU/cell. Additionally, L929 cells were mock 
infected with PBS to determine baseline IFNβ and ISG expression. After a 1h 
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adsorption period, the inoculum was removed, the cells were washed once with 
1x PBS, and whole media was added. At the specified timepoints, media was 
removed, the cells were washed once with 1x PBS, and cell lysates were 
harvested and RNA was extracted using acidic guanidinium thiocyanate-phenol-
chloroform extraction [172]. The RNA was then DNAse treated and precipitated 
via phenol-chloroform extraction. Following precipitation, 1μg of RNA was 
reverse transcribed using random hexamer primer and qRT-PCR was carried out 
as described above with primer sets obtained from PrimerBank. The sequences 
of these primers may be found in the Supplemental Materials associated with this 
manuscript. Data was first normalized to GAPDH to account for any differences 
in total RNA level between samples. Data from the wild-type SINV, D355A, and 
N376A infections were then also normalized to nsP1 to account for differences in 
viral RNA levels that were present. Fold change in IFNβ and ISG expression was 
then calculated relative to what was observed during mock infection. 
 
Mouse Experiments. Four-week old C57BL/6 mice were obtained from Jackson 
Laboratory and were inoculated in the left, rear footpad with 1000 PFU of virus in 
diluent (1x PBS) in a volume of 10μL. Mock-infected animals were injected with 
diluent alone. Mice were monitored for neurological signs of disease and 
weighed twice daily. A total of 130 mice were used in this study. For mortality 
studies, 2 biological replicates were completed with 4 animals were used per 
group, with a total of 4 groups. For titer studies, 6 animals were used per group, 
with a total of 3 groups, and a total of 5 timepoints. Eight additional mock infected 
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mice were harvested and paired with the above timepoints. Neurological scoring 
was as follows: 0 = No signs of overt disease, and normal behavioral activity; 1 = 
Abnormal trunk curl, grip, or tail weakness (1 of 3); 2 = Abnormal trunk curl, grip, 
or tail weakness (2 of 3); 3 = Absent trunk curl, lack of gripping, tail paralysis; 4 = 
Pronounced dragging of one or more limbs; 5 = hind or fore limb paralysis. On 
the termination day for each experiment or when mice met endpoint criteria 
(neurological scores of 5 or 4 if the animal was unable to obtain food or water), or 
weight loss greater than 20% of initial body weight, the mice were sedated with 
isoflurane and euthanized by thoracotomy. Blood was then collected and serum 
obtained by collecting blood in serum separator tubes. Following exsanguination, 
tissues were collected by dissection. Tissues were then placed in 1x PBS and 
homogenized using Kimble BioMasher II closed system micro tissue 
homogenizers. Ankle tissue was processed by bead beating using a Bead Ruptor 
4 (Omni International). The infectious virus present in the tissue was quantified 
by plaque assay. 
 For histology, uninfected and SINV infected mice brains were removed at 
day 7 post infection and were divided in half sagitally. One half was used to 
assess viral titer (described above), while the remaining half was fixed in 4% 
formaldehyde and sectioned in paraffin. Tissue sections were then stained with 
haematoxylin and eosin (H&E). Pathological changes were scored by a board 
certified veterinary pathologist (through the Comparative Pathology Core 
Services facility, Iowa State University) in the indicated categories and regions of 
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the brain were scored as follows: 0=normal, 1=minimal, 2=mild, 3=moderate, 
4=severe.   
 
Detection of viral genome and cytokine transcripts in mouse tissues. To 
measure the level of viral genome and cytokine transcripts in tissues of infected 
mice, RNA was extracted from tissue homogenate using acidic guanidinium 
thiocyanate-phenol-chloroform extraction. The RNA was then DNAse treated and 
precipitated via phenol-chloroform extraction. Following precipitation, 1μg of RNA 
was reverse transcribed using Protoscript II reverse transcriptase (NEB) and 
random hexamer primer. The RNA genome was detected using BrightGreen 
Express qPCR master mix (Abmgood) and the following primer set specific for 
nsP1= F: 5-AAGGATCTCCGGACCGTA-3, and R: 5-
AACATGAACTGGGTGGTGTCGAAG-3. A standard curve of known 
concentrations was used to determine the absolute quantities of viral genomic 
RNAs. Cytokine transcripts were detected using TaqMan Fast Advanced Master 
Mix and the Applied Biosystems TaqMan Array Mouse Immune Response plates 
(Catalog number:4414079) according to manufacturer’s instructions.    
 
Neuron Viability. Neuron viability was determined using a previously described 
method of ethidium bromide and acridine orange staining [173-175]. SK-N-BE(2) 
cells were seeded in a 96-well plate and, upon reaching 80-90% confluency, 
were inoculated with either wild-type SINV or one of the capping mutants at an 
MOI of 30 IU/cell. After a 1 h adsorption period, the inoculum was removed, the 
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cells were washed once with 1x PBS, and DMEM/F12 media was added. At 
24hpi, cell viability was assessed using ethidium bromide/ acridine orange 
staining described in Ribble et al. Briefly, the 96-well plate was centrifuged at 
1,000 RPM for 5 min using an Allegra 25R model centrifuge (Beckman Coulter) 
with inserts for 96-well plates. Following centrifugation, 8μL of EB/AO dye 
solution (100μg/mL ethidium bromide and 100μg/mL acridine orange in 1x PBS) 
was added to each well. Cells were viewed using an epifluorescence 
microscope. Tests were done in triplicate and a minimum of 100 total cells per 
well were counted using ImageJ. 
 
Animal Ethics and Research. This study was carried out in strict accordance 
with the recommendations described in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The protocol was 
approved by the Institutional Animal Care and Use Committee of the University of 
Louisville (Approval #17-140). All manipulations which could result in acute pain 
or distress were performed under isoflurane anesthesia.  
 
Statistical Analysis. Unless otherwise stated, the quantitative data presented in 
this study represent the means of data from a minimum of three independent 
biological replicates. The in vivo studies described in this study were performed 
in duplicate using two independent preps of viral stocks. An area-under-the-curve 
approach was used to statistically assess the growth curve data presented in 
Figure 3.1D to determine the differences in viral growth kinetics through the 
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course of the assay. Comparative samples were statistically analyzed as 
previously described [137], using variable bootstrapping where appropriate. The 
survival data presented in Figure 3.6 were statistically analyzed using the log 
rank test. Student’s t test was used to determine the P values associated with 
individual quantitative data sets. Significance for data presented in Figure 3.10 
was determined using the Benjamini and Hochberg correction, and the corrected 
p-Values are shown in Fig. 3.10 panel B. 
 
Results 
Altering Capping Efficiency Is Detrimental To Viral Growth Kinetics In 
Neurovirulent SINV In Vitro. 
Given our previously reported findings describing the molecular phenotypes 
of the nsP1 mutants in tissue culture models of infection, we were interested in 
characterizing how altering ncgRNA production impacted SINV infection in vivo. 
However, our previous characterizations of the capping mutants were done using 
a Toto1101-derived strain of SINV, which is tissue culture adapted and does not 
cause disease in adult wild type mice. Rather than rely on very young mice or 
mouse models with deficiencies in IFN competency to assess pathogenesis, we 
elected to change the SINV strain used to allow assessments in adult wild type 
mice. Thus, we incorporated the D355A and N376A nsP1 mutations into the AR86 
background of SINV, a neurovirulent strain capable of causing lethal disease in an 
adult mouse model.  
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To confirm that these point mutations had similar phenotypes in the AR86 
background as compared to the previously used Toto1101-derived background, 
the proportion of capped and noncapped genomic RNAs were quantified in BHK-
21 cells at 16hpi (Figure 3.1A-C). For wild type AR86 SINV, approximately half of 
the genomic RNA was found to be capped. This is consistent with what was 
previously found for the Toto1101-derived SINV, which also exhibited a 
capped:noncapped ratio of 1:1 at the equivalent time during infection [99]. 
Specifically, the D355A nsP1 mutation resulted in production of an RNA population 
consisting of 4-fold more capped RNA than noncapped RNA, whereas the N376A 
nsP1 mutation produced a population with 4-fold more noncapped RNA than 
capped RNA (Figure 3.1A).  When compared to wild type AR86, the D355A mutant 
produced significantly more capped vRNA and significantly less ncgRNA (Figure 
3.1B and C). Conversely, the N376A mutant produced significantly less capped 
vRNA and significantly more ncgRNA compared to wild type SINV. Although the 
absolute magnitude by which capping efficiency was affected by the nsP1 
mutations appears to be different in the AR86 strain compared to that observed for 
the previously used Toto1101-derived strain, the trend of the D355A mutation 
increasing capping efficiency and the N376A mutation decreasing capping 
efficiency remained the same [171]. 
In addition to confirming the impact of the nsP1 mutations on vRNA capping 
in the AR86 background, viral growth kinetics were also assessed in BHK-21 cells 
(Figure 3.1D). Similar to what we have reported previously, increasing the capping 
efficiency of nsP1 with the D355A mutation resulted in an approximately 1.5 log 
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decrease in viral titer over the course of infection. Likewise, decreasing capping 
efficiency with the N376A mutation also resulted in a significant decrease in viral 
growth kinetics. While the phenotype associated with the N376A mutant was more 
dramatic in the AR86 strain than what was reported in our previous study, this 
might be explained by the fact that the AR86 strain of SINV is not adapted for 
replication in tissue culture like the previously used Toto1101 strain. Therefore, the 
impact of the N376A mutation on replication is likely exacerbated in tissue culture 
systems for the AR86 strain, leading to the significantly reduced viral growth 
kinetics seen in Fig. 3.1D.  
To further confirm that the nsP1 mutants did not introduce gross lifecycle 
defects in the AR86 background, viral translation was measured. To assess how 
the nsP1 capping mutations affected viral translation, BHK-21 cells were infected 
with either wild type SINV or one of the nsP1 capping mutants, and the relative 
expression of the SINV nsP2 protein was detected via Western blotting (Figure 
3.2A). Densitometry analysis of the fully cleaved form of nsP2 revealed no 
quantitative differences across the SINV AR86 nsP1 mutant strains (Figure 3.2B). 
Despite no apparent differences in fully processed nsP2 levels, increased levels 
of nonstructural polyprotein were detected in the SINV nsP1 D355A mutant via 
comparative densitometry (Figure 3.2C). Furthermore, comparing the total signal 
detected by the anti-nsP2 polyclonal serum reveals slightly enhanced 
nonstructural gene expression in the D355A nsP1 mutant, consistent with our 
previous observations using the Toto1101-derived nsP1 mutants. These data are 
suggestive of increased or ongoing nonstructural protein synthesis in the D355A 
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background. As supported by the equivalent levels of fully processed nsP2, the 
processing of the nonstructural polyprotein likely occurs at a rate that is unaffected 
by the level of translation of the polyprotein. Thus, increasing the capping efficiency 
of the nsP1 protein led to increased nonstructural gene expression. Unlike what 
was previously found, the N376A decreased capping mutant showed no difference 
in viral translation compared to wild type SINV.   
On the basis of our previous examinations of the Toto1101-derived SINV 
nsP1 mutants, we postulate that differences in viral translation may be more 
pronounced during the earliest stages of infection. Previously we have utilized 
nanoluciferase reporter viruses to quantitatively assess viral gene expression in a 
highly sensitive manner. Unfortunately, the inclusion of a nanoluciferase reporter 
into the nsP3 protein of SINV AR86 has been found to be highly attenuating, 
precluding the detailed quantitative assessment of early SINV AR86 translation.  
In addition to viral translation, viral RNA synthesis / accumulation was also 
assessed to determine if the nsP1 capping mutations affected RNA kinetics in the 
AR86 strain of SINV. Similar to what was shown in the Toto1101-derived 
background, there were no significant differences for any of the vRNA species 
produced by either nsP1 mutant at any of the measured timepoints compared to 
wild type SINV (Figure 3.3A-C) [171].  
Taken together, we can conclude that the D355A and N376A nsP1 
mutations affect capping efficiency and viral nonstructural protein expression in the 
AR86 strain of SINV in a manner that is similar to the previously used Toto1101-
derived background. We can also conclude that the decreases seen in viral titer 
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between the nsP1 capping mutants and wild type SINV are not due to deficits in 
viral translation or RNA synthesis, but are rather due to changes in the proportion 
of ncgRNA produced by each mutant. Overall, the recapitulation of the original 
D355A and N376A capping phenotypes in the AR86 background provided a 
means by which the biological impact of the ncgRNAs on viral infection and 
pathogenesis could be assessed using an adult wild type mouse model. However, 
since our data suggest that the early events of the viral lifecycle may be altered by 
modulating capping efficiency, we decided to first characterize the engagement of 
the AR86-derived nsP1 mutants with the host innate immune response at a cellular 
level prior to utilizing a small animal model of SINV infection [171]. 
 
Modulating ncgRNA Production Alters The Host Type-I Interferon Response 
To SINV Infection.  
 The capacity of the host cell to detect viral infection and mount an antiviral 
response by upregulating interferon and interferon stimulated gene (ISG) 
expression is an important aspect of viral infection. As such, we were interested in 
determining whether changes in viral capping efficiency would impact the 
stimulation of the host type-I IFN response. To assess the extent to which the nsP1 
mutants elicited an interferon response, interferon competent L929 cells were 
infected with either wild type SINV or one of the capping mutants and then the 
expression of IFNβ was measured at the transcriptional level using qRT-PCR 
(Figure 3.4A). For this experiment, in addition to quantitatively assessing IFNβ 
transcripts throughout the viral lifecycle, we also quantified the transcript 
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abundance of select ISGs with well-established times of maximal expression post 
viral infection, so that we could more accurately determine the host antiviral 
response over the course of infection [176]. As such, CXCL10 and IFIH1 were 
used to determine the ISG expression at 6 and 8hpi, Viperin and MX2 at 16hpi, 
and OAS2 and BST-2 at 24hpi (Figure 3.4B-E).  
Infection with the D355A mutant resulted in significantly reduced IFNβ 
expression compared to wild type SINV at 8 and 16hpi, while N376A infection 
resulted in significantly greater IFNβ expression at 6 and 24hpi (Fig. 3.4A).  In 
regards to ISG transcript levels, infection with the N376A mutant resulted in 
significantly increased ISG expression compared to wild type SINV at 6hpi, but 
transcript abundance was  roughly equivalent to wild type infection at 8hpi (Figure 
3.4B-D). However, by 24hpi, ISG expression levels were once again significantly 
increased (Figure 3.4E). In contrast, ISG expression levels in response to the 
D355A mutant was significantly decreased compared to wild type SINV until 24hpi, 
where OAS2 expression was still significantly decreased, but BST2 expression 
was similar to wild type.   
Overall, infection with the increased capping mutant, D355A, led to a mostly 
decreased host antiviral response compared to what was seen during wild type 
infection, while the decreased capping mutant, N376A, elicited a response that 
was mostly increased compared to wild type SINV. Taken together, these results 
illustrate that modulating ncgRNA production has a significant impact on the 




Sensitivity To Type I IFN Correlates With Capping Efficiency In Tissue 
Culture. 
Given that altering capping efficiency affected viral gene expression, and 
altered the induction of the host type-I IFN response, we were interested to see if 
changes in ncgRNA production affected the virus’s sensitivity to IFN treatment. In 
other words, we have shown that altering capping efficiency impacts how much 
IFN is produced, but does altering SINV capping efficiency affect the virus’s 
capacity to resist IFN treatment when the cells are treated with equal amounts of 
type-I IFN? To determine whether changes in ncgRNA production affected the 
sensitivity of the nsP1 mutant viruses to exogenous type-I IFN, IFN-competent 
L929 cells were infected with either wild type or a SINV nsP1 mutant virus and 
recombinant type-I IFN was then added at 0, 1, 2, 3, or 4 hours post infection and 
viral titer was measured at 24hpi (Figures 3.5A-C) [175].  
During wild type SINV infection, viral titer was reduced by ~2 logs when IFN 
was added at 0 hpi, with maximum titer increasing regularly as the time of IFN 
addition was delayed. IFN treatment at 4 hpi did not impact SINV AR86 replication 
as viral titers were equivalent to those of the no IFN control (Fig. 3.5A).  The D355A 
mutant, which has increased capping efficiency and viral gene expression, was 
found to be significantly more resistant to type-I IFN treatment early during 
infection compared to wild type SINV, with viral titer only being reduced by ~ 1 log 
when IFN was added at 0 hpi (Fig. 3.5B). As with wild type SINV, the maximal titer 
of the D355A mutant steadily increased as the addition of type-I IFN was delayed 
to later times post infection; however, the relative differences in titer between the 
108 
 
IFN treated infections and non-treated control indicate that the D355A mutant was 
significantly more resistant to the impacts of type-I IFN overall. In contrast, the 
N376A mutant, which has decreased capping efficiency, was found to have wild-
type equivalent sensitivity to IFN when added at 0 and 1 hpi, but the N376A mutant 
remained sensitive to the addition of type-I IFN at later times during infection 
(Figure 3.5C). Surprisingly, even when IFN was added as late as 4hpi, the titers of 
the N376A mutant remained decreased compared to those of the IFN negative 
control, revealing that the N376A mutant remains sensitive to IFN for a longer 
period of time than wild type SINV.  
To enable the comparative analysis of the impact of type-I IFN on the viral 
infections of the capping mutants compared to wild type infection, the differences 
in viral titers between the IFN treated and the control infections for each virus and 
time point were calculated. The differences in titer found for each nsP1 mutant 
were then made relative to the corresponding differences observed for the wild 
type infection (Fig. 3.5D). These data illustrate that during the early stages of viral 
infection the D355A nsP1 mutant is approximately 2-fold more resistant to type-I 
IFN than wild type SINV AR86; however, by 2 hpi the advantage has largely waned 
and the level of IFN resistance is similar to that observed during wild type infection. 
Similarly, comparing the resistance of the N376A mutant to wild type SINV AR86 
further reveals that decreasing capping efficiency correlates with significantly 
increased sensitivity to type-I IFN up to at least 4 hours post infection. 
It is interesting to note that, in the absence of IFN treatment, infections of 
the IFN-competent L929 cells with wild type SINV or the D355A mutant resulted in 
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roughly equivalent viral titers at 24hpi. This is different than what was observed 
previously in BHK-21 cells, where the D355A mutation resulted in significantly 
decreased viral titer (Fig. 3.1D). This difference in phenotypes between the two 
cell lines is likely due to the fact that the L929 cells are IFN competent and will 
produce IFN in response to viral infection while BHK-21 cells are incapable of 
doing so, resulting in differential viral replication rates due to the host response to 
viral infection in conjunction with the apparent differences in IFN sensitivity.  
Overall, the sensitivity of the SINV nsP1 mutants to IFN reflects the 
differences seen in capping efficiency. Increased capping efficiency resulted in the 
D355A mutant being more resistant to type-I IFN early during infection when 
compared to wild type SINV. Likewise, decreased capping efficiency resulted in 
the N376A mutant being more sensitive to type-I IFN. This indicates that both the 
viral response to type-I IFN and the virus’ ability to mitigate the effects of IFN 
expression on viral replication are altered depending on the level of ncgRNA 
produced during infection.  
 
Increasing Capping Efficiency Significantly Attenuates Neurotropic SINV In 
A Mouse Model.  
 As the capacity to avoid the elicitation of the host innate immune response, 
and the capacity to disregard the effects of the host type-I IFN response are vital 
to alphaviral replication and pathogenesis, the above data suggested that altering 
ncgRNA production could have profound effects on viral replication and 
pathogenesis in vivo. We hypothesized that, due to the nsP1 D355A mutant’s 
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increased resistance to type-I IFN and generally reduced activation of ISG 
expression, mice infected with the nsP1 D355A mutant would experience disease 
severity similar to wild-type SINV infection, perhaps with the mean survival time 
being potentially decreased due to increased IFN resistance. Conversely, we 
hypothesized that mice infected with the N376A mutant would experience more 
mild disease and decreased mortality because of the mutant’s increased sensitivity 
to IFN and the greater expression of ISGs in response to infection in tissue culture 
models of infection. To test our hypothesis, we infected 4-week old male and 
female C57BL/6 mice with 1,000 PFU of SINV AR86 wild-type, nsP1 D355A, or 
nsP1 N376A via rear footpad subcutaneous inoculation. Mock infected mice were 
inoculated with PBS in the same manner. When infected with wild type SINV, adult 
C57BL/6 mice displayed significant weight loss as well as severe neurological 
symptoms, including rapid onset paralysis of the limbs, blindness, and seizures at 
approximately day 6 post infection (Figure 3.6A and B). Infection with wild type 
SINV also led to significant mortality, with infected mice having a mean survival 
time of ~6 days post infection (Figure 3.6C). Likewise, mice experimentally infected 
with the decreased capping mutant N376A exhibited similar weight loss and 
neurological symptoms as wild type infected mice. However, the onset of disease 
in the N376A infected mice was delayed compared to wild-type SINV, with 
neurological symptoms starting at 5 dpi and the mean survival time being ~7 dpi, 
a full day later than what was seen with wild type SINV. In addition, a slightly 
greater proportion of mice survived when infected with the N376A mutant as 
opposed to wild type SINV. This increase in survival may be due to the delay in 
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the N376A mutant to cause neurological symptoms, allowing the mice to be slightly 
older, and therefore better able to resist severe, lethal encephalitis [80, 177, 178]. 
 Surprisingly, the increased capping mutant virus D355A was significantly 
attenuated in mice. Compared to the previous two viruses, mice infected with the 
D355A mutant experienced minimal weight loss, milder neurological symptoms, 
and significantly reduced mortality, with all but one mouse surviving to the end of 
the study. Given that these mice did in fact show mild neurological and non-
neurological symptoms and reduced weight gain compared to mock infected mice, 
we concluded that the nsP1 D355A increased capping mutant virus is indeed 
capable of causing pathogenesis, although the severity of disease is significantly 
reduced compared to wild type infection.  
The trends seen in morbidity and mortality between the mice infected with 
wild type SINV versus the capping mutants were further reflected in H&E stained 
sections of the brains of infected and uninfected mice (Figure 3.7). The brain 
sections of both wild type and N376A infected mice displayed numerous lesions 
consisting of lymphocytic meningitis; perivascular cuffing, which is indicative of 
immune cell infiltration; and neuronal apoptosis, which left open pockets in the 
tissue (Figure 3.7A). In addition, mice infected with either wild type SINV or the 
N376A mutant had significant pathology in terms of inflammation, neuronal 
degradation, and glial cell proliferation in multiple areas of the brain. Pathology 
was highest in the cerebrum and the midbrain / brainstem, but lesions were also 
found in the hippocampus and medulla oblongata of some mice (Figure 3.7B). 
Conversely, the brains of the D355A infected mice resembled mock infected mice, 
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with no immune infiltration, cell death, or other signs of pathology in any area of 
the brain. Given that viral killing of neurons is the speculated cause of encephalitis 
and paralysis in SINV infection, the differences in tissue damage and neuron death 
seen between the D355A mutant and the other two viruses were not unexpected, 
as the D355A infected mice did not exhibit signs of encephalitis or limb paralysis  
(Figure 3.6B) [179, 180]. 
Collectively, these data suggest that modulating the production of ncgRNA 
has significant impacts on alphaviral pathogenesis. Overall, the nsP1 N376A point 
mutation, which increased ncgRNA production through decreased capping 
efficiency, resulted in delayed disease progression and mortality compared to wild 
type SINV in vivo. However, severity of neurological symptoms and pathology in 
the brain were unaffected. In contrast, the nsP1 D355A point mutation, which 
decreased ncgRNA production through increased capping efficiency, resulted in 
significantly decreased mortality, mild neurological symptoms, and little to no 
pathology in the brain. While the presence of mild symptoms and a lack of weight 
gain in the D355A infected mice do suggest that the virus was capable of trafficking 
to the brain and replicating, these data do not eliminate these as being possible 
reasons for the decreases in pathogenesis seen thus far.   
 
Attenuation Of Viral Pathogenesis Is Not Due To Deficits In Viral 
Dissemination Or Replication.  
Given that the D355A and N376A nsP1 mutants showed decreased viral 
titers in tissue culture model systems compared to wild type SINV (Figure 3.1D), 
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we hypothesized that the reduction in mortality seen in Figure 3.6 was due to poor 
viral replication, dissemination, or a change in virus tropism for the brain.  In order 
determine the impact of modulating capping efficiency on viral replication and to 
confirm that the nsP1 D355A mutant did in fact make it to the brains of infected 
mice, we measured viral titer at the site of inoculation and in the serum at 1dpi as 
well as in the brain at 7dpi. By comparing the viral titers of the nsP1 D355A mutant 
to wild type SINV in these tissues, we were able to determine if decreasing 
ncgRNA production impacts viral pathogenesis by altering viral replication, 
dissemination, or tropism to the brain. If the D355A mutant had defective 
dissemination or tropism to the brain, then we would expect to see wild type titers 
at the site of inoculation, as well as potentially the serum, but an absence of viral 
titer in the brain. Alternatively, if viral titers for the D355A mutant are significantly 
decreased in the ankle, serum, and brain, then this would suggest that the 
decreases seen in pathogenesis were due to poor viral replication and 
dissemination.  
Surprisingly, in contrast to what was expected given our tissue culture data, 
viral titers in the ankle, serum, and brain were more or less equivalent between 
wild type SINV and the two nsP1 mutants (Figure 3.8). The similar titers found in 
the ankle between the nsP1 mutants and wild type SINV show that the reduced 
pathogenicity of the nsP1 D355A mutant is not due to a defect in viral replication 
at the site of inoculation (Fig. 3.8A). Likewise, since the nsP1 D355A mutant had 
titers equivalent to wild type levels in the serum, we can also conclude that viral 
dissemination was not negatively impacted (Fig. 3.8B). Finally, while the viral titer 
114 
 
of the D355A and N376A mutant were both slightly decreased in the brain 
compared to wild type SINV, the lack of a significant difference indicates that 
increasing capping efficiency did not alter viral tropism to the CNS and that there 
is no overt defect in viral replication (Fig. 3.8C). Interestingly, while these results 
are different from what was previously observed during infection of BHK-21 cells 
(Figure 3.1D), the trends seen in the serum and brain, where the N376A mutant 
has slightly decreased viral titer compared to wild type SINV and the D355A 
mutant, was similar to what was seen with the L929 cells (Figure 3.5).  
To further complement our observations regarding the induction of the host 
innate immune response to infection (as in Figure 3.4A), we quantitatively 
assessed IFNβ transcript levels in the ankles of the experimentally infected mice 
at 24hpi. Despite differences in the overall magnitudes of type-I IFN induction, we 
found no differences between our in vitro and in vivo assessments (Supplemental 
Figure 3.1).  
 The dissemination of the SINV mutants to the brain was further confirmed 
when viral RNA levels in the brain were measured (Figure 3.8D). While the nsP1 
D355A mutant did exhibit slightly lower vRNA abundance in the brain compared to 
wild type SINV, it was not found to be a statistically significant difference and is 
likely an artifact due to differences in when the brain tissue was collected. While 
the majority of the D355A infected mice survived to 7 dpi when the brain tissue 
was collected, all of the wild type infected mice met endpoint criteria prior to 7dpi. 
As such, the adaptive immune response in the D355A infected mice that survived 
to 7 dpi may have started to clear some of the infected cells serving as viral RNA 
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reservoirs from the brain, resulting in the decreased vRNA abundance compared 
to the wild type infected mice that did not survive long enough to mount a similar 
response. N376A RNA levels in the brain were also found to be equivalent to that 
of wild type SINV. These results indicate that, while the D355A and N376A nsP1 
point mutations were capable of reducing viral titer in tissue culture, they were not 
detrimental to viral replication in mouse models of infection.  
Taken together, these data suggest that both the increased capping virus 
D355A and the decreased capping virus N376A were capable of trafficking to the 
brain from the site of inoculation, and were capable of replicating to high titers 
within the brains of experimentally infected adult mice. It is also interesting to note 
that neither viral titer nor viral genomic RNA abundance correlated with death, as 
there were multiple mice which survived infection that had greater viral titer and 
vRNA abundance in the brain than mice which died. Overall, these results led us 
to conclude that the attenuation of pathogenesis seen in the D355A mutant were 
not due to either deficits in viral replication or tropism. 
 
Increasing Capping Efficiency Does Not Affect Viral Induction Of Neuronal 
Apoptosis. 
Since we did not find any significant differences in viral replication or tissue 
tropism / dissemination, we next determined if decreased mortality in the D355A 
mutant was due to an altered capacity to induce neuronal death, as virally induced 
apoptosis of neurons in the brain, brainstem, and spinal cord have been shown to 
be responsible for the severe neurological symptoms that arise during SINV 
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infection [89, 179-181]. In addition, our previous study characterizing the nsp1 
capping mutants in tissue culture showed that both the D355A and N376A mutant 
demonstrated increased cell viability in BHK cells compared to wild type SINV, 
supporting the possibility that the D355A mutant might have differences in cell 
viability in neurons as well [171]. In light of our previous study as well as the striking 
difference in cell death between the D355A and wild type infected brains (Figure 
3.7), we hypothesized that increasing capping efficiency would decrease the virus’ 
capacity to kill neurons. To test this hypothesis, we infected SK-N-BE(2) cells with 
either wild type SINV or one of the capping mutants and determined cell viability 
24 hours after infection using ethidium bromide and acridine orange staining. 
Infection with the decreased capping N376A mutant resulted in significantly greater 
cell viability compared to either wild type SINV or the D355A mutant, which both 
exhibited roughly similar levels of cell death (Figure 3.9). Interestingly, these 
results suggest that increasing ncgRNA production leads to increased cell survival 
in tissue culture models of infection, while decreasing ncgRNA production does 
not seem to impact the virus’ capacity to kill neurons in tissue culture models of 
infection. Given this, we can conclude that the differences seen in tissue damage 
between the D355A and wild-type SINV infections in Figure 3.7 are not solely due 
to deficits in the D355A mutant’s capacity to kill neurons. Instead, the above results 
suggest that the neuronal death seen during SINV infection in mice may be largely 





Differential ncgRNA Expression Alters The Immune Response To Infection.  
Because the differences in morbidity and mortality between the D355A 
nsP1 mutant and wild type SINV infected mice could not be explained by 
reductions of viral titer or the capacity to induce neuronal death, we next 
questioned whether differences in pathogenesis could be due to an altered host 
immune response. Given the reduced immune infiltration and inflammation seen 
in the D355A infected mice compared to the wild type or N376A infected mice 
(Figure 3.7), we expected infection with the D355A mutant to also result in the 
decreased expression of pro-inflammatory genes. To survey the immune response 
to SINV nsp1 mutant virus infections, RNA was isolated from whole brain 
homogenates of infected mice at 7 dpi or upon meeting endpoint criteria, and the 
level of select cytokine and chemokine transcripts were measured via a qRT-PCR 
based array. Out of the transcripts measured, 50 were found to be significantly 
increased in wild type infected versus mock infected mice (Figure 3.10A). When 
wild type and D355A infections were compared, we found 15 inflammatory 
cytokines and chemokines whose expression was determined to be significantly 
decreased (using a Benjamini-Hochberg corrected p-Value) by a magnitude 
greater than 2-fold (Figure 3.10B). Individual box and whisker plots of these 
statistically significant transcripts may be found in Fig. 3.10C. These included 
chemokines involved in recruiting innate immune cells, such as CCL2, CCL3, and 
CXCL10, as well as important drivers of inflammation like IFNβ, IL1β, TNFα. In 
particular, the expression of CCL2 and CCL3 have been highly correlated with 
areas of the brain experiencing high levels of gliosis and apoptosis, which is 
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consistent with the differences in pathology scoring in those areas between the 
D355A mutant and wild type SINV (Figure 3.7B) [182]. Interestingly, several of the 
proteins that had decreased expression in the D355A infected mice compared to 
wild type infected mice where identified by gene ontology as being part of the 
extrinsic apoptotic pathway [183, 184]. The identification of proteins involved in 
apoptosis, specifically Fas, Il1α, Il1β, and TNFα, is consistent with the significant 
decrease in neuronal apoptosis seen in the H&E stained sections of mice infected 
with the D355A mutant. Surprisingly, IFNγ expression, which has been previously 
shown to be important for noncytolytic clearance of virus from neuronal cells, was 
not found to be significantly different in either mutant compared to wild type (Figure 
3.10A) [185].  As expected, the decreases seen in the expression of these 
chemokines and pro-inflammatory cytokines are consistent with the reduced 
immune infiltration and tissue damage seen in Figure 3.7.  
Overall, these data show that the D355A increased capping mutant has 
significantly reduced pathogenicity in a wild type mouse model of infection 
correlating with decreased expression of multiple pro-inflammatory molecules at 
the transcriptional level. Furthermore, the above data suggests that it is likely the 
host response rather than viral replication per se that determines the extent of 
alphaviral pathogenesis. This is supported by the finding that the wild type and 
D355A viruses both had roughly equivalent viral titers in the brain, yet wild type 
SINV had significantly increased pro-inflammatory cytokine transcript expression 
compared to the D355A mutant. While transcript levels are not synonymous with 
protein levels, the correlation between the expression of antiviral transcripts and 
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levels of inflammation in the brain suggest that antiviral protein expression likely 
follows the same trends. Taken together, it can be concluded that decreased 
ncgRNA production via increased capping efficiency leads to an altered host 
immune response, which in turn shapes alphaviral pathogenicity. 
 
Discussion 
Altering Capping Efficiency Changes Viral Sensitivity To And Activation Of 
Host Type-I IFN.  
 For Sindbis virus, the sensitivity of the virus to type-I IFN is largely 
dependent on the translation of the nonstructural proteins which are responsible 
for interfering with the IFN signaling pathway and for shutting down host 
transcription [174, 186-188]. When capping efficiency was increased with the 
D355A mutant, nonstructural gene expression was also found to be increased, 
although the magnitude was not as drastic as was previously seen with the 
Toto1101-derived background (Figure 3.2). However, this may not be necessarily 
representative of what happens early during viral infection where the magnitude of 
effect is likely to be more pronounced.  While we were previously able to 
characterize early viral translation in the Toto1101-derived background using a 
nanoluciferase reporter incorporated into nsP3, the construction of the identical 
reporter in the AR86 background resulted in significant attenuation. However, 
given that we have previously shown that the differences in viral translation for the 
D355A mutant were more pronounced early during infection, and that increasing 
capping was correlated with increased genomic translation in both viral 
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backgrounds (Fig. 3.2C), it is likely that the D355A mutant in the AR86 background 
would also follow this trend [171].  Increased translation of the viral proteins would 
allow the virus to more quickly shut down IFN signaling pathways, host PAMP 
sensors, as well as host transcription and translation, which would explain why the 
D355A mutant showed reduced IFNβ and ISG expression and greater resistance 
to IFNβ treatment [175, 189-191]. In addition, the altered IFNβ and ISG expression 
seen with the capping mutant likely reflects changes in the virus’ abilities to both 
avoid detection by the host as well as suppress the cellular antiviral response 
[186]. Because IFNβ and ISG transcript abundance was normalized to viral RNA 
levels, we know that the differences seen in antiviral transcript expression are not 
simply due to differences in viral replication or the amount of vRNA present. 
Rather, the changes observed in IFNβ and ISG expression for the D355A and 
N376A nsP1 mutants are likely due to both differences in PAMP production and 
their abilities to shutoff host transcription and translation. This is supported by the 
correlation between ncgRNA production, which are a viral PAMP, and IFNβ/ISG 
expression (Fig. 3.1B and Fig. 3.4) [189, 190].  Also, the fact that the D355A mutant 
showed increased resistance to type-I IFN even when IFN was added concurrently 
with the virus demonstrates how increasing capping efficiency allows the virus to 
more readily mitigate the effects of the IFN response. The D355A mutant’s 
increased resistance to IFN at such an early timepoint suggests that, in addition to 
increased translation, the mutation may also affect how quickly the virus 
progresses through the viral life cycle. Increasing the production of capped 
genomic vRNA could potentially give the virus a head start on translation of the 
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viral proteins responsible for shutting down the host IFN response, allowing the 
D355A mutant to be more resistant to IFN treatment early during infection.   
 
Noncapped Genomic vRNAs Are Critical For SINV Pathogenesis In Mice. 
 The ability to resist and shut down the type I IFN response has been shown 
to be one of the major determinants of virulence for SINV. For example, the AR86 
strain of SINV is a virulent strain known to efficiently suppress the type I IFN 
response and cause lethal neurotropic disease in adult mice. The genetically 
similar Girdwood strain only partially inhibits the type I IFN response, and thus is 
avirulent in adult mice [101]. Given the above finding that the D355A mutant was 
both more resistant to type I IFN treatment and resulted in decreased ISG 
production compared to wild type virus, we were surprised to find that this mutant 
did not cause severe disease or mortality in mice. Equally surprising was the result 
that infection with the N376A mutant was similarly as severe and lethal as infection 
with wild type SINV, despite N376A being more sensitive to IFN treatment and 
stimulating more ISG expression in vitro. Taken together, this suggests that there 
may be a balance between inhibiting and activating the IFN response which results 
in pathogenesis, and that tipping the scales too far in either direction causes the 
virus to become avirulent. Furthermore, our results indicate that ncgRNA play a 
critical role in determining whether the virus is neurovirulent or avirulent, as 
decreasing ncgRNA production with the D355A mutation resulted in significant 
decreases in morbidity and mortality while increasing ncgRNA production with the 
N376A mutation resulted in fully neurovirulent virus and lethal disease.  
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Although the D355A mutation had a much more striking impact on morbidity 
and mortality, the N376A mutation also had noticeable impacts on alphaviral 
pathogenesis, namely a delay in the onset of symptoms, an increased mean 
survival time, and a moderate increase in overall survival compared to wild type 
SINV. The idea that inhibiting capping efficiency is detrimental to alphaviral 
infection is not novel and multiple compounds and drugs have been developed to 
specifically target nsP1 capping activity [166-169]. Our results do not negate the 
idea that decreasing or inhibiting capping efficiency is an effective means of 
combating alphaviral infection, but rather suggest that there is a threshold which 
needs to be reached before decreasing capping efficiency will be significantly 
detrimental to viral pathogenesis. Likewise, our mortality studies imply that the 
virus is much more sensitive to increasing capping efficiency and that this novel 
approach may be more effective in limiting the severity of viral disease.    
 During SINV infection, the development of severe encephalitis which leads 
to paralysis and death is caused by the extensive apoptosis and necrosis of 
neurons in the brain and CNS, which is believed to be virally induced [86, 179, 
181, 192]. While apoptosis is the fate of many infected cells and neurons, a 
significant portion of uninfected neurons are killed during viral infection due to 
glutamate excitotoxicity [87]. The lack of apoptosis and necrosis seen in the brains 
of mice infected with the D355A mutant (Fig. 3.7) suggests that, during in vivo 
infection, decreasing ncgRNA production by increasing nsP1 capping efficiency 
leads to decreased viral induction of neuronal apoptosis and therefore decreased 
glutamate release, resulting in the reduced death of infected and uninfected 
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neurons. However, when tested in tissue culture cells, infection with the nsP1 
D355A mutant resulted in wild type levels of neuronal death, while infection with 
the N376A mutant, which showed extensive signs of neuronal apoptosis and 
necrosis in vivo, resulted in significantly increased neuron survival. Since 
increasing capping efficiency did not seem to impact the virus’ ability to induce 
neuron death in tissue culture, these data suggest that the apoptosis and necrosis 
of neurons seen in the brain during SINV infection is largely mediated by an 
external force, such as by the host immune response.  This is supported by 
previous studies which propose that the majority of neuronal death due to 
apoptosis and glutamate excitotoxicity may be the work of T cells and astrocytes, 
rather than being directly virus-induced [193, 194].  
 Another surprising result was that disease severity did not correlate with 
increased viral titer or vRNA abundance. This is most clearly seen in the N376A 
infected mice, where the viral titers and vRNA levels in the brains of mice that died 
are interspersed among those which survived. In addition, surviving mice from both 
the D355A and N376A infections had titers and vRNA levels in the brain that were 
roughly equivalent to those found in the mice infected with wild type SINV which 
died. Furthermore, neither viral titer nor vRNA burden in the brain correlated with 
levels of inflammation seen in Figure 3.7. This suggests that, during SINV infection, 
high viral titer alone is not sufficient to cause severe disease in mice. In addition, 
altering capping efficiency did not significantly impact viral replication, 
dissemination, or tropism. This was illustrated by the roughly wild type-equivalent 
titers found in the ankle, serum, and brain indicating that both of the capping 
124 
 
mutants were able to efficiently replicate at the site of inoculation, disseminate into 
the blood, and traffic to the brain. However, the slight decrease in N376A titer seen 
in the blood and brain does potentially suggest that dissemination may be slightly 
delayed or impaired when capping efficiency is decreased, and may explain the 
slight increase seen in mean survival time. 
Unfortunately, one question we were unable to answer in this study was 
whether viral capping efficiency in brain tissue was similarly affected by the nsP1 
mutations, as was previously shown in tissue culture model systems and with 
recombinant proteins [124, 171]. Regrettably, the limitations in sensitivity of 
previously established and currently available assays render us unable to directly 
answer this question, as these methods require a significant quantity of high-
quality viral RNA that is difficult to obtain from brain tissue. This is likely due to the 
fact that an exceptionally few number of cells in the brain are required to be 
infected for the manifestation of significant disease and the appearance of 
endpoint criteria. However, the altered pathogenesis seen in mice in the absence 
of any obvious defects in viral replication, dissemination, or tropism lead us to 
believe that the point mutations incorporated are still altering capping efficiency 
and are not significantly affecting nsP functions in other ways. Previously 
characterized mutations in nsP1 which resulted in loss of neurovirulence did so by 
significantly altering vRNA synthesis and/or processing of the nonstructural 
polyprotein, which typically resulted in decreased viral titer in animal models of 
infection [100, 101, 170, 195]. Given that neither the D355A nor N376A mutations 
significantly altered viral titer or vRNA burden during SINV infection in vivo, nor 
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negatively impacted vRNA synthesis or viral translation in vitro , we can conclude 
that the phenotypes seen both in tissue culture and in animal models of infection 
are the result of the mutations altering ncgRNA production through modulating 
capping efficiency. Furthermore, given the conserved effect of the D355A and 
N376A nsP1 point mutations in multiple alphaviruses in tissue culture and in vitro, 
it is likely that these mutations still respectively increase or decrease capping 
efficiency in vivo, but the magnitude that capping efficiency is altered may be 
different from what was previously seen in tissue culture [124, 171]. 
 
Noncapped Genomic RNAs Determine SINV Virulence by Modulating the 
Host Inflammatory Response.  
 Infection with the D355A capping mutant resulted in the decreased 
expression of multiple cytokines and chemokines associated with the recruitment 
of immune cells, regulating inflammation, and apoptosis. While there were a small 
number of cytokines found to be differentially expressed during infection with the 
N376A mutant compared to wild type SINV, they did not implicate any pathways 
in particular. Interestingly, expression of anti-inflammatory transcripts such as 
TGFβ and IL-10 was found to be similar between D355A and wild type infection, 
while others such as SOCS1 were found to be significantly decreased. This 
suggests that the decreased inflammation seen with the D355A mutant is due to 
decreased activation of antiviral and inflammatory pathways rather than increased 
expression of anti-inflammatory cytokines. The decreased activation of these 
antiviral pathways are likely due to both the reduced release of DAMPS from dying 
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cells and decreased sensing of viral PAMPS. The first is supported by the 
identification of several of the affected proteins being involved in apoptosis as well 
as the decreased level of cell death seen with the D355A mutant. The second is 
supported by the decreased IFNβ and ISG expression seen during D355A infection 
(Figure 3.4). The decreased sensing of viral PAMPS may be due to the D355A 
mutant either being more efficient at inhibiting the cell’s viral sensors and signaling 
pathways through shutoff of host transcription or could be due to the D355A mutant 
producing fewer noncapped RNA, which are an established PAMP [189, 190]. 
Given that viral infection in animals is a continuous process, shut-off of cellular 
transcription and suppression of the IFN response in tissues likely does not occur 
as efficiently or completely as it does in cell culture, where all the cells are infected 
simultaneously. Therefore, the decreased production of inflammatory cytokines 
seen with the D355A mutant is likely due to reduced detection of DAMPs and 
PAMPs caused by decreased cell death and decreased production of ncgRNA. 
How exactly the ncgRNA are sensed by the host during viral infection is not 
currently known and is an ongoing interest in the Sokoloski lab. While there is 
some evidence that suggests that the noncapped RNA produced during alphaviral 
infection are at least in part sensed by RIG-I, it is unknown if this is also true for 
ncgRNA and there may be additional methods for detecting noncapped vRNA that 
have yet to be characterized [190, 196]. Overall, the correlation between 
decreased inflammation and decreased ncgRNA production leads us to conclude 




In conclusion, we have identified a novel determinant of Sindbis virulence 
which operates through a separate mechanism than those previously described. 
Specifically, decreasing the production of ncgRNA by increasing capping efficiency 
results in the loss of neurovirulence which we believe is due to the reduced 
production of RNA PAMPs that would otherwise cause excess inflammation and 
wide-spread cell death in the brain (Fig. 3.11). The D355A mutation differs from 
previously identified nsP1 virulence determinants in that it does not negatively 
affect viral titer nor resistance to IFN, such as is seen with the SINV nsP1 cleavage 
mutant T538I and the 6 nsP1 mutations characterized in Ross River virus [97, 170]. 
The D355 residue in nsP1 is also unique from the aforementioned mutation sites 
in that it is very highly conserved among SINV strains as well as across both the 
old and new world alphaviruses.  While the results of this paper indicate that the 
production of ncgRNA is critical to SINV pathogenesis, more work is needed to 
further characterize the mechanisms by which ncgRNA contribute to alphaviral 





Figure 3.1.  Point mutations in nsP1 of AR86 SINV result in changes in 
capping efficiency and negatively impacts infection in mammalian cells. (A) 
Quantitative assessment of SINV RNAs produced during infection of BHK-21 
cells with either wild type SINV or either of the nsP1 mutants at an MOI of 5 
PFU/cell. RNA was collected at 16hpi and treated as described in Materials and 
Methods. Graphs depicting the relative quantities of noncapped (B) or capped 
(C) genomic RNAs produced during infection of BHK-21 cells with either wild 
type SINV or either of the nsP1 mutants at 16hpi. (D)One-step growth kinetics of 
the individual capping mutants and the parental wild-type SINV in BHK-21 cells 
infected at an MOI of 5 PFU/cell. All the quantitative data shown represent 
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means of results from three independent biological replicates, with error bars 
representing standard deviation of the means.  Statistical significance was 







Figure 3.2.  Increasing capping efficiency increases translation of SINV 
AR86 nonstructural polyprotein. (A) BHK-21 cells were infected with either 
wild type SINV or one of the nsP1 capping mutants at an MOI of 5 PFU/cell. 
Abundance of nsP2 was then assessed at 8hpi by Western blotting. 
Nonstructural polyprotein band marked by ▲.  The p23 polyprotein intermediate 
band (as determined by molecular weight) is marked by . Fully processed nsP2 
band marked by ●. Actin is shown as the loading control. Densitometric 
quantification of fully processed nsP2 protein (B), nonstructural polyprotein (C), 
and total nsP2 signal (D) normalized to actin levels at 8hpi. All the quantitative 
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data shown represent means of results from three independent biological 
replicates, with error bars representing standard deviation of the means.  





Figure 3.3. Altering capping efficiency does not impact AR86 SINV vRNA 
synthesis. BHK-21 cells were infected with either wild type SINV or one of the 
nsP1 capping mutants at an MOI of 5 PFU/cell. Absolute quantities of the genomic, 
subgenomic, and minus strand vRNAs produced at 4 (A), 8 (B), and 16hpi (C) were 
determined by qRT-PCR. All the quantitative data shown represent means of 
results from three independent biological replicates, with error bars representing 






Figure 3.4. Production of type-I interferon and ISGs in response to SINV 
nsP1 capping mutants.  L929 cells were infected at an MOI of 10 PFU/Cell with 
either wild-type SINV or an individual capping mutant. Cell lysates were collected 
at 6, 8, 16, and 24hpi and transcript expression levels for IFNβ (A) and the 
selected ISGs (B-E) were determined by qRT-PCR for their respective times post 
infection. Data was normalized to GAPDH and nsP1 and calculated relative to 
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uninfected controls. All the quantitative data shown represent means of results 
from three independent biological replicates, with error bars representing 
standard deviation of the means. Statistical significance was determined by 





Figure 3.5. Analysis of SINV sensitivity to type-I interferon. L929 cells were 
infected with either wild-type SINV or an individual capping mutant at an MOI of 10 
PFU/cell. At the indicated times post infection, 20 IU of recombinant Type-I IFN 
was added to the growth medium and the cells were incubated for a period of 24 
hours. (A-C) Viral titers were quantified via plaque assay, and (D) the relative 
sensitivity of the viruses was determined by comparing their growth relative to 
untreated controls. All the quantitative data shown represent means of results from 
three independent biological replicates, with error bars representing standard 








Figure 3.6. Increased vRNA capping efficiency reduces SINV AR86 mortality 
and pathogenesis. 4-week old male and female C57BL/6J mice were either mock 
infected or infected with 1,000 PFU of SINV AR86 wild-type , D355A , or N376A  
via rear footpad subcutaneous inoculation. Each data point represents a single 
animal from either experimental replicates. The experimentally infected mice were 
assessed over a 14 day period. (A) Animals were weighed twice daily. Weights are 
shown relative to initial weight after being infected. (B) Mice were scored based on 
a 1-5 scale for neurological response. (C) Kaplan-Meier analysis indicates the WT 
median survival time (MST) at ~6.4 days and the N376A mutant MST at ~7 days. 
The P values indicated on the figure were determined by the Log-rank test. 
*=p<0.05, ****=p<0.0001. Data shown were pooled from 2 independent 






Figure 3.7. Increased capping efficiency leads to decreased pathology in the 
brain. A) Representative H&E stained sagittal sections of the midbrain (20x 
magnification) from mock, wild-type, or capping mutant infected mice at 7dpi or at 
the time at which end point criteria was met. The brains of SINV wild-type and 
N376A infected mice show large amounts of perivascular cuffing, immune 
infiltration, and cell death not present in the mock and D355A infected mice. Scale 
bar = 0.1mm. B) Ranked pathology scoring of indicated sections of the brain from 
infected mice. Data points indicate scoring for each experimental animal, 




Figure 3.8. Viral replication is largely unaffected by altered capping in vivo. 
(A-C) Tissues were harvested at the indicated times post infection and viral titer 
was determined via plaque assay. (D) Viral genomes were measured by qRT-
PCR. The data points indicate the individual titers for each experimental animal, 
and the mean values shown are the geometric means of at least four biological 
replicates from two independent experiments, with the error bars representing the 
geometric standard deviations of the means. ▲= mice that met endpoint criteria 





Figure 3.9. Neuron viability increased with decreased capping efficiency. SK-
N-BE(2) neurons were infected at an MOI of 30 PFU/Cell with either wild-type SINV 
or an individual capping mutant. Cell viability was determined at 24hpi using 
ethidium bromide/ acridine orange staining and is represented as the proportion of 
viable cells out of total cells counted. A minimum of 100 total cells per well were 
counted using ImageJ. All the quantitative data shown represent means of results 
from three independent biological replicates, with error bars representing standard 














Figure 3.10. Increased viral capping efficiency results in reduced expression 
of pro-inflammatory genes in the brain. (A) Cytokine transcript levels in the brain 
at 7dpi were measured by qRT-PCR. Data was normalized to GAPDH and 
calculated relative to uninfected controls. (B) Volcano plot showing the fold change 
in transcript expression between wild type SINV and the D355A mutant. Green 
points are transcripts that have greater than a 2-fold change in expression and are 
significant according to the Benjamini and Hochberg corrected p value. (C) 
Cytokines and chemokines whose expression was significantly increased 
compared to uninfected controls and exhibited a significant difference in 
expression between wild type SINV and the D355A mutant that was greater than 
2-fold. All the quantitative data shown represent means of results from at least 
three independent biological replicates, with center lines representing the median, 
+ representing the mean, boxes representing the interquartile range, error bars 
representing standard deviation of the means, and • representing outliers as 
determined by Tukey’s method. Statistical significance was determined by 





Figure 3.11. Proposed model of how increasing genomic vRNA capping 
negatively impacts viral pathogenesis. Infection of the brain with the 
decreased capping nsP1 mutant N376A results in increased production of 
ncgRNA , which likely act as PAMPs (left). The increased levels of PAMPs in the 
brain results in increased activation of the immune response, leading to 
excessive neuroinflammation and neuropathology. Conversely, infection of the 
brain with the increased capping nsP1 mutant D355A results in decreased 
production of ncgRNA, and therefore decreased production of PAMPs (right). 
The decreased levels of PAMPs results in a more moderate immune response 






Supplemental Figure 3.1. Quantitative Analysis of IFNβ Transcript Levels in 
SINV AR86 Infected Ankle Tissue. Ankle tissues harvested from either mock 
infected, wild type SINV AR86, or SINV AR86 nsP1 mutant infected animals were 
harvested at 1 day post infection and homogenized. Total cellular RNA was 
isolated from the tissue homogenates and assessed via qRT-PCR to determine 
the relative transcript abundances of the IFNβ gene. Quantitative data shown are 
the means of at least three biological replicates, with the error bars representing 
the standard deviation of the means. Statistical analysis of the data, as by 
Student’s T-Test, indicated no significant differences between the SINV AR86 





Supplemental Table 3-1. Primers used in this study. 
Linker= F: GTTCAGAGTTCTACAGTCCGACCCATC 
SINVg.CapAssay= R: CGTCTACGTTTACTACTGGCTTCTCC 
SINV.nsP1 =F: AAGGATCTCCGGACCGTA,  
R: AACATGAACTGGGTGGTGTCGAAG 
SINV.E1= F: TCAGATGCACCACTGGTCTCAACA,  
R: ATTGACCTTCGCGGTCGGATACAT 
Mam.18S= F: CGCGGTTCTATTTTGTTGGT,  
R: AGTCGGCATCGTTTATGGTC 
IFIT2= F: AGTACAACGAGTAAGGAGTCACT,  
R: AGGCCAGTATGTTGCACATGG 
SHB= F: CTGATGACTACTCCGATCCCTT,  
R: GGGGTGTCGTACAACTGGATG 
CXCL10= F: CCAAGTGCTGCCGTCATTTTC,  
R: GGCTCGCAGGGATGATTTCAA 
IFIH1= F: AGATCAACACCTGTGGTAACACC,  
R: CTCTAGGGCCTCCACGAACA 
Viperin= F: TGCTGGCTGAGAATAGCATTAGG,  
R: GCTGAGTGCTGTTCCCATCT 
MX2= F: GAGGCTCTTCAGAATGAGCAAA,  
R: CTCTGCGGTCAGTCTCTCT 




BST2= F: TGTTCGGGGTTACCTTAGTCA,  
R: GCAGGAGTTTGCCTGTGTCT 
IFNβ= F: AAGAGTTACACTGCCTTTGCCATC,  
R: CACTGTCTGCTGGTGGAGTTCATC 






DISCUSSION AND FUTURE DIRECTIONS 
 
Research Summary 
 Although the production and prevalence of the noncapped genomic RNA 
(ncgRNA) during alphaviral infection had been previously established, prior to 
these efforts, very little was known about their importance to viral infection and 
pathogenesis. By using mutations whose impacts on nsP1 enzymatic activity had 
been previously established in a similar virus outside of the context of infection 
using recombinant nsP1 protein, we were able to show that the capping activity 
of SINV nsP1 could be intentionally modulated during viral infection [124]. By 
altering the capping efficiency of nsP1 through the use of these point mutations, 
we were able to show that decreasing ncgRNA production negatively impacts 
viral infection. In characterizing these nsP1 capping mutants, we revealed that 
the decreased viral growth kinetics caused by decreasing ncgRNA production 
was not due to decreases in viral translation or vRNA synthesis, but rather was 
due to deficits in particle production. This marks the first time that the RNA 
capping activity of nsP1 has been directly implicated in determining particle 
production in any of the alphaviruses, outside of nsP1 mutations which altered 
production of viral proteins or vRNA synthesis. Furthermore, our results indicate 
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that the ncgRNA specifically play an important role in regulating viral particle 
production. 
In addition to the described impacts on viral infection in vitro, our data also 
establishes that the ncgRNA are vital to alphaviral pathogenesis, as decreasing 
ncgRNA production resulted in reduced morbidity and mortality as well as 
decreased inflammation, immune infiltration, and cell death in the brain. 
Altogether, this was found to be due to the decreased expression of inflammatory 
cytokines in response to infection. While previous research with RRV had loosely 
correlated changes in ncgRNA production with disease progression, we were 
able to use the SINV nsP1 mutants to definitively show that the ncgRNA are 
major determinants of alphaviral pathogenesis [97, 99]. Furthermore, while 
ncgRNA had been previously found to be associated with activation of type-I IFN 
at the cellular level, we were able to expand upon this and show how altering 
ncgRNA production directly impacted activation of, as well as viral sensitivity to, 
type-I IFN. We also demonstrated that the ncgRNA were important for 
determining the host inflammatory response. Despite the wealth of evidentiary 
data connecting ncgRNAs to pathogenesis via the host response, exactly how 
the ncgRNA dictate disease severity and the host antiviral response is still 
unknown. 
 
Evolutionary Conservation of ncgRNA 
Multiple alphaviruses have been shown to produce ncgRNA during 
infection, indicating the ncgRNA production is conserved among the alphavirus 
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genus. Since producing ncgRNA results in a greater immune response without 
lending an obvious advantage to viral replication in regards to viral gene 
expression or vRNA synthesis, there must be a separate reason for alphaviruses 
to have conserved their production as they are translationally inert and incapable 
of initiating infection by themselves. Our data suggests that alphaviruses may 
have conserved ncgRNA production in order to more efficiently replicate at the 
cellular level via the efficient production of viral particles. This is supported by the 
data in Chapter 2, where we showed that increasing capping impairs particle 
production in vitro. Nonetheless, in cellular models with an intact IFN response 
system, and in adult mouse models of infection, viral titer was similar between 
the D355A and wild type viruses (Chapter 3). It should be noted that in the IFN-
competent tissue culture model this was not due to increased infectious particle 
production in the D355A mutant, rather the production of wild type virus was 
reduced while D355A remained comparatively unaffected in regards to titer. We 
postulate that the equivalency between the wild type and D355A mutant in this 
scenario is due to the reduced induction of, and increased resistance to, type-I 
IFN by the D355A mutant which resulted in a slight advantage over the wild type 
virus despite decreased particle production. Similarly, although viral titer was not 
significantly different between D355A and wild type SINV in mice, this doesn’t 
necessarily mean that the D355A did not still experience a defect in particle 
production in vivo, but rather could simply be explained as an effect of the D355A 
mutant being more resistant to IFN. If the ncgRNA play an important role in 
particle production in both in vitro and in vivo infections, then alphaviruses may 
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have conserved ncgRNA production in order to more efficiently replicate at the 
cellular level. This would be especially important in the context of the reservoir 
host, where severe disease does not develop in response to wild type alphaviral 
infection. In this case, the increased particle production and higher viral titer that 
occurs when ncgRNA are present would be advantageous to the virus as it would 
allow for better viral transmission.   
A second possibility is that alphaviruses produce ncgRNA because they 
are beneficial to viral transmission between the vertebrate host and invertebrate 
vectors, and vice versa. Previous work has shown that mosquitos fed alphaviral 
particles containing primarily capped genomic RNA have a significantly lower 
midgut infection rate compared to those that were fed primarily ncgRNA 
containing particles [123]. Furthermore, it has also been shown that, during 
vertebrate infection, the particles found in the serum are those associated with 
ncgRNA [123]. The fact that the particles containing mostly ncgRNA were also 
more infectious in mosquito models of infection strongly suggests that the 
ncgRNA are important for alphaviral transmission between the vertebrate host 
and the invertebrate vector. It is also interesting to note that infection of 
mosquitos using particles that contained primarily capped genomic RNA elicited 
a significantly weaker immune response in the midgut compared to the particles 
that contained mostly ncgRNA. The induction of an immune response in the 
midgut by the ncgRNA may function to help disrupt the midgut barrier, allowing 
for better dissemination of the virus throughout the mosquito. While more work 
would need to be done to characterize the importance of the ncgRNA to 
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invertebrate infection as a whole, this does suggest that the ncgRNA play a 
critical role in establishing viral infection of the mosquito vector. 
 
Role of ncgRNA in Particle Production 
One particularly interesting finding that was described in Chapter 2 was 
that decreasing ncgRNA production alone had a significant detrimental impact to 
viral particle production. While it is unknown how the ncgRNA aid in viral particle 
production, there are multiple scenarios where the ncgRNAs could affect particle 
production.  
One such scenario is that the ncgRNA bind a unique set of proteins that 
allow them to manipulate the cellular environment in favor of particle production 
(Fig. 4.1A). It stands to reason that if the capped genomic RNA are being 
translated in a manner similar to host mRNA, in that the RNA is lined with 
multiple ribosomes which all simultaneously translate the RNA, then the capped 
genomic RNA are not going to be able to efficiently interact with viral or host 
factors. In contrast, because the ncgRNA are not translated as they lack the 
canonical cap structure, translating polysomes would not form. This would allow 
the ncgRNAs to be available to interact with host/viral factors as well as maintain 
any secondary RNA structures that may be required for protein or RNA 
interaction [197]. Therefore, it is likely that the ncgRNA bind a different suite of 
proteins than the capped vRNA. While this has not been shown for alphaviral 
RNAs, the notion that non-translating RNAs bind different proteins than 
translating RNAs has been shown for eukaryotic mRNAs, especially in regards to 
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P-body formation and translational silencing [198, 199]. In relation to particle 
production, this means that the ncgRNA may either recruit proteins necessary for 
efficient particle production or sequester proteins which may inhibit particle 
assembly away from the vRNA population as a whole. This would allow the 
ncgRNA to mold the intracellular environment into one that is favorable for 
efficient particle production. Thus, by decreasing ncgRNA production with the 
D355A mutation, the virus’s capacity to form a pro-assembly environment may 
have been reduced. 
A second possibility is that the ncgRNA prevent premature disassembly of 
the nucleocapsid during the assembly process (Fig. 4.1B). Following entry of the 
viral particle into the host cell, the incoming nucleocapsid core is disassembled 
by the binding of the 60S ribosomal subunit to the capsid protein [57]. Because 
the capped genomic RNA are associated with polysome formation and 
translation, there would be an abundance of 60S ribosomal subunits bound to 
them or in close proximity. Once the virus begins assembling progeny particles, 
continued association of the 60S ribosomal subunit with the genomic RNA could 
potentially trigger premature disassembly of the nucleocapsid core before it can 
be adjoined to the viral glycoproteins and released as a mature particle. 
Therefore, it is likely that the nucleocapsid assembly microenvironment benefits 
from being devoid of ribosomal components and translating RNAs. Because the 
ncgRNA are not translated, they would not recruit the 60S ribosomal subunit, and 
would not trigger premature disassembly of the viral capsid. Thus, it is possible 
that the ncgRNA may serve as a buffer between the areas where viral translation 
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and particle assembly occur. However, as we know that both capped RNA and 
ncgRNA are packaged into viral particles and the packaging of capped vRNA is 
essential for viral infection, the ncgRNA buffer between the translating capped 
vRNA and the particle assembly area cannot by too restrictive, or no capped 
vRNA would be packaged into particles. The purpose of the ncgRNA buffer zone 
may then be to dilute the translating vRNA that are being packaged into particles, 
effectively reducing the amount of 60S ribosomal subunit present in a 
concentrated area, allowing for more efficient particle production.  
 Finally, the ncgRNA may act as allosteric effectors which aid in the 
formation of the nucleocapsid core (Fig. 4.1C). While this has not been explicitly 
shown for alphaviruses, the ability of viral RNA to allosterically regulate 
nucleocapsid assembly has been demonstrated in Rous sarcoma virus as well as 
bacteriophage MS2 [200]. In Rous sarcoma virus, particle assembly is inhibited 
by intramolecular interactions between different domains of the capsid protein 
Gag which prevent its dimerization. Binding of the viral RNA to Gag induces one 
or more conformational transitions that allows the protein to dimerize and 
assemble into a lattice structure [201]. In MS2, in addition to inducing capsid 
assembly, the viral RNA is also thought to act as a scaffold that directs the 
assembly of capsid proteins into the proper conformation for the viral particle 
[202]. Given that the specifics of the alphaviral capsid assembly are not currently 
known, it is possible that the ncgRNA may function as allosteric effectors that 
dictate the efficient assembly of nucleocapsid cores [66]. Therefore, decreasing 
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ncgRNA production may have resulted in the decreased presence of an effector 
which may allow for efficient particle assembly.  
 
Role of ncgRNA in Pathogenesis 
A major finding of the in vivo characterization of the nsP1 mutants in 
Chapter 3 was that decreasing ncgRNA production resulted in little to no 
morbidity or mortality in mice. Interestingly, this was not due to defects in viral 
replication or tissue tropism, but rather this phenomenon was largely due to 
decreased expression of inflammatory molecules at the transcript level in the 
brain. This indicates that the ncgRNA are determinants of disease severity and 
that their presence plays a role in the activation / quality of the immune response. 
While exactly how the ncgRNA determine the host inflammatory response is 
unknown, it is likely to be at least in part due to the ncgRNA acting as PAMPs. 
Due to its lack of a 5’ cap structure and likely increased secondary structure as 
they are not translated, the ncgRNA would serve as PAMPs that could be 
detected by multiple host innate immune proteins. As briefly stated in the 
introduction, RIG-I is responsible for detecting noncapped RNA, specifically 
RNAs with a 5’ di- or triphosphate [203]. While the vast majority of the ncgRNA 
produced by SINV have a 5’ monophosphate which is undetected by RIG-I, 
~20% of the ncgRNAs contain a 5’ di- or triphosphate, meaning that a small 
portion of the ncgRNA can potentially be detected by RIG-I [99]. In addition to 
being noncapped, the extensive branched secondary structures of ncgRNA may 
also serve as a PAMP for detection by innate immunity. Because translation of 
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the RNA by ribosomes would result in the disruption of RNA secondary structure, 
it is likely that the non-translating ncgRNA would have significantly more 
secondary structure present than the capped genomic RNA, making the ncgRNA 
a target for dsRNA sensors like MDA5 and LGP2 as well.  
The specific importance of MDA5 vs RIG-I in detecting alphaviral infection 
has not yet been firmly established; and in general seems to be dependent on 
viral strain, cell type, and mouse background [114, 204, 205]. The variation seen 
in the importance of RIG-I and MDA5 signaling to restricting viral infection may 
be in part due to the two proteins activating distinct response pathways that may 
be different or less prevalent depending on the context of infection. While there 
has been some evidence for CHIKV that RIG-I and MDA5 are redundant, work 
with flaviviruses has shown that they have unique roles in inducing expression of 
innate immune genes [206-208]. Therefore, detection of the ncgRNA by either 
one or both RIG-I and MDA5 may be responsible for the high levels of 
inflammation seen with wild type SINV infection and may account for why 
inflammation is reduced when ncgRNA production is decreased. However, more 
work is required to determine which of these immune sensors are specifically 
detecting the ncgRNA during alphaviral infection and to further establish that the 
role of the ncgRNA as PAMPS is directly tied to disease severity in vivo. 
 
ncgRNA as a Novel Antiviral Target 
Given the importance of the 5’ cap to viral infection, it is unsurprising that 
the alphaviral capping enzyme has been a target for antiviral research. There 
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have been multiple compounds developed to inhibit nsP1 capping activity. Some 
of these compounds directly interact with nsP1 to inhibit vRNA capping. For 
instance, MADTP-314 is known to directly disrupt the GTPase activity of nsP1, 
while FHA and FHNA were found to directly inhibit the MTase activity of nsP1 
[166, 209]. Although the exact mechanisms by which these compounds inhibit 
nsP1 is not known, they will likely become more clear in the near future now that 
the structure of nsP1 has been determined. Other compounds disrupt nsP1 
capping activity in a more indirect manner. Many of these, such as ribavirin, are 
GTP analogs which can outcompete GTP for the nsP1 binding site and prevent 
the capping reaction from occurring [168, 210]. Targeting SAM, which donates 
the methyl group to make the cap, is another route which prevents RNA capping 
that has been used for drug development [211]. Examples include Sinefungin, a 
SAM analog which has been shown to be able to inhibit transmethylation and 
disrupt nsP1 capping activity [212]. It is important to note that although many of 
these drugs have been shown to significantly reduce alphaviral replication in 
vitro, as of yet, none have been tested for efficacy against alphaviral infection in 
vivo.  
The success of the nsP1 capping mutants to significantly impact morbidity 
and mortality in response to alphaviral infection highlights the ncgRNA as a novel 
target for antiviral development. While the antiviral studies mentioned above all 
focused on inhibiting nsP1 capping efficiency, which would result in increasing 
ncgRNA production, we have shown that SINV is significantly more sensitive to 
decreasing ncgRNA production than to equivalent increases in ncgRNA 
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production. This was proven to be true for both viral replication at the molecular 
level as well as disease progression as a whole. The fact that SINV was less 
sensitive to decreases in capping activity is of particular interest in regards to the 
above mentioned antivirals, since if they do not sufficiently inhibit capping in vivo, 
they may not be efficacious. Furthermore, it is not known how increasing 
ncgRNA production, and therefore PAMP production, partway through infection 
may impact severity of disease, as treatment in the clinical setting often begins 
after the manifestation of pathology. Therefore, despite the counterintuitive 
approach of enhancing a viral replication process, decreasing ncgRNA 
production may be a more viable option for the development of viable antiviral 
therapies or preventatives than trying to reduce capped genomic RNA production 
to the point that it negatively impacts the virus. 
 
Future Directions 
 While the work shown here establishes the importance of the ncgRNA to 
viral infection, there is still relatively little known about their specific functions 
during viral infection and the mechanism by which they influence pathogenesis. 
Therefore, future studies would endeavor to further characterize the ncgRNA and 
their roles during alphaviral infection. As stated above, this would include 
determining how ncgRNA influence particle production, identifying unique binding 
partners, characterizing how they are detected by innate immune sensors, and 
determining the potential of ncgRNA for the development of antivirals. 
Additionally, while ncgRNA production has been experimentally shown for SINV 
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and RRV, characterizing ncgRNA production in other alphaviruses such as 
CHIKV or VEEV would help to establish their importance to alphaviral infection 
as a whole. Given the highly conserved nature of nsP1, it is likely that the 
inefficiency of 5’ capping seen with SINV is true of the other alphaviruses as well, 
although the proportion of ncgRNA produced relative to capped genomic RNA 
will likely differ. In addition, future work which determines how alphaviruses 
evolve in response to mutations in nsP1 which alter capping efficiency, 
specifically whether there are direct reversions or compensatory mutations in the 
viral genome, may be able to shed further light on why ncgRNA production is 
conserved among the alphaviruses. 
Also, although the work described here establishes the importance of the 
ncgRNA to alphaviral infection in mammals, how ncgRNA production affects 
infection of invertebrates has yet to be determined. It will be particularly 
interesting to see if altering ncgRNA production has a similar impact on viral 
infection and the antiviral response in whole mosquito models of infection. Since 
previous studies have shown that even altering the amount of ncgRNA present 
during the initial round of viral replication has drastic impacts on mosquito 
infection, maintaining these differences in ncgRNA production throughout the 
course of infection with the D355A capping mutant will potentially result in even 
greater deficits to viral infection. 
Given the impact of altering ncgRNA production on disease severity, 
another future direction would include assessing the potential of the D355A 
mutant for vaccine development. While using the single point mutation by itself 
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may not result in a viable vaccine due to the high likelihood of reversion, 
development of a virus with multiple mutations which affect capping may yield 
greater stability of the capping phenotype. A second approach would be to 
incorporate the D355A mutation into an already existing vaccine strain, such as 
VEEV TC83 and CHIKV 181/25, in order to reduce the high incidence of adverse 





Figure 4.1. Potential roles for ncgRNA in alphaviral particle production. (A) Viral  
RNA (red lines) may bind different host or viral factors depending on whether or not the 
vRNA is capped. The ncgRNA may aid in particle assembly by recruiting proteins which 
make particle assembly more efficient (in purple and blue), or sequestering proteins 
which would impair particle assembly (in orange and green). (B) The 60S ribosomal 
subunit (large yellow half circles) are known to trigger particle disassembly. Therefore, 
having many translating capped vRNAs in the same area where particle assembly takes 
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place may lead to increased association of the 60S ribosomal subunit with viral capsid 
(red triangles) and lead to premature disassembly of the particles (Left). In this case, a 
potential function of the ncgRNA may be to serve as a buffer between the translating 
vRNAs and areas of particle assembly to prevent premature particle disassembly 
(Right). (C) Lastly, the ncgRNA may regulate particle assembly by acting as allosteric 
effectors. Binding of the capsid protein to the ncgRNA may allow for easier initiation of 
particle assembly. Additionally, the ncgRNA may act as a scaffold which direct proper 
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Abbreviation   
ANOVA   Analysis of Variance 
AUD    Alphavirus Unique Domain 
Bax    Bcl-2 Associated X protein 
Bcl-2    B-cell lymphoma 2 
BHK    Baby hamster kidney cells 
BST-2    Bone Marrow Stromal Cell Antigen 2 
CCL2    C-C Motif Chemokine Ligand 2 
CCL3    C-C Motif Chemokine Ligand 3 
CHIKV   Chikungunya virus 
CNS    Central nervous system 
CXCL10   C-X-C Motif Chemokine Ligand 10 
DAMP    Damage-associated molecular pattern 
dpi    Days post infection 
dsRNA   Double-stranded RNA 
EB/AO   Ethidium bromide/ acridine orange 
EEEV    Eastern Equine Encephalitis virus  
ER    Endoplasmic reticulum 
FBS    Fetal Bovine Serum 
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GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GFP    Green Fluorescent Protein 
H&E    Haematoxylin and eosin  
hpi    Hours post infection 
IFIH1    Interferon Induced With Helicase C Domain 1 
IFIT1 Interferon Induced Protein With Tetratricopeptide 
Repeats 1 
IFN    Interferon 
IFNAR   Interferon alpha/beta receptor 
IL-1    Interleukin-1 
IL-10    Interleukin-10 
IRF    Interferon response factor 
ISG    Interferon stimulated gene 
IU    Infectious unit, International unit 
JAK    Janus kinase 
LGP2    Laboratory of Genetics and Physiology 2 
MAVS    Mitochondrial antiviral-signaling protein 
MCP-1   Monocyte chemoattractant protein 1 
MDA5    Melanoma differentiation-associated protein 5 
MEM    Minimal Essential Media 
MOI    Multiplicity of Infection 
mRNA   Messenger RNA 
MX2    Myxovirus Resistance Protein 2 
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ncgRNA   Noncapped genomic RNA 
nsP    Nonstructural protein 
OAS2    2'-5'-Oligoadenylate Synthetase 2 
ONNV    O’nyong’nyong virus 
PAMP    Pathogen-associated molecular pattern 
PBS    Phosphate Buffered Saline 
PFU    Plaque Forming Units 
PNK    Polynucleotide Kinase 
qPCR    Quantitative Polymerase Chain Reaction 
qRT-PCR   Quantitative Real Time Polymerase Chain Reaction 
RdRp    RNA dependent RNA polymerase 
RIG-I    Retinoic acid-inducible gene-I 
RppH    RNA 5’ Pyrophosphohydrolase  
RRV    Ross River virus 
RT    Reverse Transcription 
SAM    S-adenosylmethionine  
SFV    Semliki Forest virus 
SINV    Sindbis virus 
SOCS    Suppressor of Cytokine Signaling 
ssRNA   Single-stranded RNA 
STAT    Signal transducer and activator of transcription protein 
TF    Transframe protein 
TGFb    Transforming Growth Factor beta 
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TNFa    Tumor Necrosis Factor alpha 
Tyk2    Tyrosine Kinase 2 
VEEV    Venezuelan Equine Encephalitis virus  
vRNA    viral RNA 
WEEV   Western Equine Encephalitis virus  
WT    Wild type 
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